All news

Researchers working on the TEDDY study, which is aiming to understand the environmental factors involved in type 1, have found no link between viral infections and fast progression to type 1 diabetes.

The TEDDY study is following, from birth, children who have a set of genes that make them more likely to develop type 1. Some of these children have a family history of type 1, while others do not.

Over 8,000 children have been enrolled in the study and are being monitored regularly for the development of autoantibodies that signal the immune system may be about to attack the beta cells. The researchers hope that they can find a link between when the autoantibodies appear and some change in the environment that does not occur in children who don’t develop autoantibodies.

This particular study, which is just one of many small studies being carried out as part of TEDDY, looked at children who went on to develop type 1 within six months of the autoantibodies first appearing. These are known as ‘fast progressors’. Many people develop type 1 years after antibodies can be first detected, but fast progressors tend to develop it within months.

The researchers looked for evidence of a viral infection in the blood samples of fast progressors. They looked specifically in the last sample taken that was autoantibody negative and the first sample that was autoantibody positive to see if there was a virus present in the time leading up to the development of autoantibodies.

They found that there was no difference between the number of children that had a virus before quickly developing type 1 and the number of ‘control’ children who had a virus and did not develop autoantibodies. However the study team have pointed out that as the blood samples were taken three months apart, a viral infection could have occurred between the two samples being collected.

Dr Maebh Kelly, Research Communication Officer at JDRF commented, ‘This is a small study as part of the wider TEDDY programme so it is difficult to reach a firm conclusion on the role of viruses in type 1. It is possible that there may be more than one environmental factor involved in type 1 and that there could be different triggers for fast and slow progressors. TEDDY is an excellent study which could really help us understand the triggers for type 1, so we look forward to seeing more results from the study team’.

You can read more about the TEDDY study in the latest issue of our magazine, Type 1 Discovery »

Last Friday, London office workers donned their cycling shorts in JDRF's Ride to Cure Diabetes event, raising £33,500 to support JDRF's work to cure, treat and prevent type 1 diabetes

The event, which took place at The Royal Exchange, Bank, challenged 43 teams of five to push their bodies to the limit over eight-minute interval sprints on static exercise bikes. JDRF was thrilled by the high uptake, with competitors either had a personal experience of type 1 diabetes or simply relished the competitive element of the event.

Macquarie Group Foundation, the philanthropic arm of the Macquarie Group, was the main funder for the London Ride to Cure Diabetes. This is the fifth series of bike-a-thons organised by JDRF, which are happening up and down the country in cities including Salisbury, Leeds, Bristol and Manchester. 

Teams included staff from the Macquarie Group and Mistubushi, AIG, Schroders and RBS.

 The fastest team, from Spin City Schroders achieved a distance of 32,272 metres in 40 minutes. Peter Marsland, from Schroders, was crowned the ‘King of Ride’, covering 7,104 metres in eight minutes and Rafaela Pozzi, from London City Selection Group was crowned the ‘Queen of Ride’ with a distance of 5,551 metres.

 Louise Ingham, JDRF’s Regional Development Manager for London, said:

'We were really excited about this year’s Ride to Cure Diabetes and it was great to cheer on teams in London. Everyone who took part will be making a valuable contribution to our research, which aims to cure, treat and prevent this condition which has a life-long impact on those diagnosed with it and their families. We are entirely grateful to Macquarie for their generous support and all our other sponsors, who helped to make this happen. Well done to everyone who took part this year and here’s to next year’s challenge!'

Edward Beckley, European Head of Macquarie Infrastructure and Real Assets said:

'Macquarie is proud to be a key supporter of JDRF in the UK and we were delighted that the Macquarie team was able to get involved raising both vital funds and the profile of type 1 diabetes. We look forward to continuing to assist JDRF’s important work for people with type 1 diabetes and their families.'

The Ride to Cure Diabetes events are part of JDRF’s wider Cycle to Cure Diabetes campaign, which encourages the public to raise money on two wheels during 2013. So if you have been inspired by the likes of Olympians Bradley Wiggins, Victoria Pendleton and Sir Chris Hoy and want to hit the saddle, sign up today.

JDRF would like to thank this year’s other sponsors including; Watt Bikes, Boom! Cycle, Back in Action UK, The Royal Exchange, D&D London and Trainsmart.

View photos from the Ride to Cure Diabetes London 2013

The fact that the NHS is not providing insulin pumps to enough people with type 1 diabetes – compared to much higher access rates in other European nations – may be exposing them to greater risk of serious health complications, according to two diabetes charities.

Diabetes UK and JDRF expressed concerns as the UK’s first ever audit of insulin pump use, published today, revealed that just seven per cent of the estimated 247,500 UK people with type 1 diabetes use a pump.

These continually infuse insulin into the layer of tissue just beneath the skin and so help control blood glucose levels more tightly. Better blood glucose control is known to reduce the risk of long-term complications such as blindness, amputation, kidney failure and stroke. The pumps also offer a more practical alternative to multiple daily injections and help avoid hypos, which are when a person’s blood glucose level falls too low.

Usage in the UK is thought to have gone up over the last five years. But the report highlights that the seven per cent figure is still much lower than in countries such as Germany and Norway, where over 15 per cent of those with type 1 diabetes use a pump. In the US, use of insulin pumps is even more widespread, with some 40 per cent of people with type 1 having one.

The picture in the UK is slightly better for children, with 19 per cent of under-18s with type 1 using a pump, but this is still much lower than comparable European countries.

The report was published today by Ian Gallen, Fellow of the National Institute for Health and Care Excellence (NICE), and supported by the Association of British Clinical Diabetologists as well as the charities Diabetes UK and JDRF.

Diabetes UK and JDRF  are both concerned that some people with type 1 diabetes who would gain maximum benefit are continuing to be denied access to a pump.  The report suggests the UK’s poor performance is linked to the low number of healthcare professionals qualified to train people with type 1 diabetes to use a pump, with the lack of diabetes specialist nurses (DSNs) a particular problem.

The two charities are calling on the NHS to ensure that every child with type 1 diabetes is able to access specialist paediatric teams and that adult diabetes teams are commissioned to ensure access to a DSN who is experienced in pump management, which would deliver a big increase in pump usage in the UK.

Barbara Young, Chief Executive for Diabetes UK, said: 'While not everyone with type 1 diabetes wants a pump, it is important that those who would benefit and meet NICE guidance are able to access one, as pumps help some people to maintain a better level of blood glucose control than is possible through injecting insulin. 

'This means that, long term, having a pump can reduce risk of complications such as amputation and blindness, can significantly improve quality of life and play a real role in helping people to manage their own condition, which in turn can reduce the number of people with type 1 diabetes who die before their time.

'This new report suggests that getting more healthcare professionals qualified to train people with type 1 diabetes to use a pump is big part of the solution. We now need the NHS to make this happen, as part of its commitment to ensuring everyone with diabetes has the best possible chance of a long and healthy life.'

Karen Addington, Chief Executive of JDRF, said: 'Access to pumps for those living with type 1 has increased over the last five years, but at a glacial pace – from two per cent to seven per cent. JDRF has long pushed the message that increased investment in research to cure, treat and prevent type 1 diabetes and its complications is vital. But furthermore, this report highlights the crucial importance of actual access to the treatments that come from this research. After all, insulin pumps were first endorsed for UK patients by the National Institute for Health and Care Excellence (NICE) 10 years ago.'

Publisher of the report Ian Gallen said: 'Whilst the national picture is improving, we are still a good way from where we should be with pump treatment. There are people who are having problems managing their diabetes who do not have the option of an insulin pump offered to them in a timely way, because of insufficient specialist support services. The commissioners of diabetes services must study our audit so they can ensure they commission appropriate specialist diabetes services, meaning that people can quickly move to pump treatment when needed.'

This was the first comprehensive audit of insulin pump access in the UK, involving the participation of 97 per cent of hospital trusts that provide insulin pump services.

Download the full report »

You may have read reports in the news recently about a vaccine for type 1. Many of the reports suggested that a vaccine will soon be a realistic approach to preventing type 1.

An ideal vaccine would retrain the immune system and stop the attack on beta cells but there are many challenges that still need to be overcome.

JDRF-supported scientists are currently testing a vaccine to slow down the progression of type 1. The vaccine trial at Cardiff University and King’s College London hopes to stop or slow down the immune system attack on the pancreas.

This vaccine is a targeted immune therapy designed to reset a person’s immune system and slow or stop the body from damaging its own insulin-making cells in the pancreas. Preliminary research has shown that the vaccine is safe and this next step hopes to determine if the treatment is effective in people. The scientists are currently recruiting adult patients who have recently been diagnosed and have just started taking insulin to take part in the trial.

This clinical trial is just a part of JDRF’s autoimmunity programme. In FY11 JDRF spent about £20 million around the world on research aiming to understand, prevent or reverse the autoimmune attack that causes type 1. We are also currently supporting other approaches to developing a vaccine including using microparticles that could boost the regulatory cells of the immune system to get it back under control. It is possible that in the future that a combination of vaccines may work best or that different approaches will be more suited to different people. 

Our research into stopping the immune system is not only focusing on developing a vaccine for type 1 but also on developing early markers to detect type 1 so that we can in the future stop the immune attack before clinical symptoms occur.  At the time of diagnosis, many of the beta cells have already been destroyed, so by detecting the earliest symptoms of the condition we may be able to prevent it before beta cells begin to die.

A vaccine to retrain the immune system could also be beneficial to people who have had type 1 for a long time. Used in combination with a beta cell replacement therapy for example, it could prevent the immune system from attacking the new beta cells. 

Research into a vaccine is exciting but has a long way to go before it can become a reality for people with type 1 as scientists still need to learn more about how it works in people  type 1. 

JDRF funds over 25 projects in the UK every year. Each project brings us one step closer to our ultimate goal of curing type 1 diabetes. You can help us continue our important work by making a donation now.

Paul Morris, 32, from Dorchester has set himself his biggest challenge yet – cycling 229 miles from London to Paris to raise awareness of type 1 diabetes, a condition he has been living with for the past 20 years

Paul’s three-day ride, which starts on 7 June 2013, is raising vital funds to help JDRF cure, treat and prevent type 1 diabetes. 

Paul said:

'I was diagnosed with type 1 diabetes aged 12, soon after I started secondary school. Since then, I have never let it stop me doing anything I’ve wanted to do. I want to raise awareness of the condition and show other people living with it that they can do these challenges too and raise money for a great charity like JDRF at the same time. I’m really excited to be taking part in this year’s London to Paris bike ride and I can’t wait to cross the finish line by the Eiffel Tower. I would encourage others to sign up to a JDRF challenge today.'

Thanks to new technology, Paul’s treatments have changed over the years, from having multiple daily insulin injections, to now being on a pump. He said:

'Last year I was lucky enough to qualify for an insulin pump on the NHS. It’s a small device that pumps insulin through a small cannula placed just below the skin. It gives me much better control of how much insulin I have in my system, and it mimics the way a healthy pancreas would actually work.'

Paul is fortunate – many people with type 1 diabetes do not have access to an insulin pump.

Paul will be cycling the London to Paris challenge with others who also live with the condition - it’s his most arduous challenge yet and he is calling on people to support the cause. 

Local people and businesses have already been very generous in support of Paul’s charity bid. A special thanks goes to Bay Engineering (Weymouth), Arnold Jones Associates (Dorchester), Joy Lane and Co (Dorchester) and Precision Acoustics Ltd (Dorchester).

 Jon Medcraft, Senior Challenge Events Fundraiser, said:

'We are delighted that Paul has decided to do the challenge on behalf of JDRF and we wish him and the team the very best of luck.'

If you would like to donate to JDRF and track Paul’s progress, visit his fundraising page. You can also donate by texting the code PLTP94 and your amount to 70070 (e.g. PLTP94 £10).

JDRF has a number of cycling events on offer in 2013/14 – visit the JDRF Cycle to Cure Diabetes pages and start putting the wheels in motion for the cure

William Chanter, 16, from Crockham Hill in Kent and friend Tom Baker, 15, from Alton are taking on the challenge of a lifetime this summer to raise vital funds for JDRF

The pair will be sailing 60 miles around the Isle of Wight in just a 29er dinghy – leading some to compare the challenge to climbing Snowdon on a pogo stick. 

The teen sailors both live with type 1 diabetes, which affects 29,000 children in the UK. Both want to prove that it doesn’t stop you living your life – and both want to do something positive to raise awareness. 

Their journey will be a record breaking challenge for three reasons. Nobody has ever attempted to circumnavigate the island in such a vessel (a 29er dinghy) before.  Nobody under the age of 17 has attempted it – and nobody living with type 1 diabetes has ever attempted it either. William and Tom hope that it will take eight hours to complete if the weather is favourable.

William, a sixth form pupil at Oxted School, was diagnosed aged six. He has to do multiple blood glucose tests and insulin injections every day. He said:

'The challenge is really important to us – we’re passionate about sailing but just as passionate about raising awareness of type 1 and funds for JDRF. A huge thank you to everyone who has supported us so far and we can’t wait to break some records now.'

Tom, an Eggar’s School pupil, was diagnosed two years ago. He added:

'When I was diagnosed with type 1 it was a huge shock and it took a while to adjust to living with the condition but I was determined not to let it affect my sailing.'

William and Tom will be attending an open day at the Bough Beech Sailing Club, Edenbridge, on Saturday 18 May to talk about their up-and-coming challenge, along with supporters JDRF and Team Blood Glucose.

Nicole Gerrard, Senior Fundraiser for the area, said:

'William and Tom are an inspirational pair. The challenge that they are doing is amazing but to be the first pair with type 1 to attempt it is even more incredible! We are wishing the pair every success in their challenge and thanking them for raising awareness and funds for us – bon voyage to them both!'

Paul Buchanan, CEO of Team Blood Glucose, said:

'Both William and Tom share a common goal, to demonstrate that anyone living with this chronic, lifelong condition can achieve anything if they put their mind to it.'

Support for the teenagers has been fantastic with the whole community getting behind the adventure, including friends and family. Special thanks to the Bough Beech Sailing Club, Team BG, Sanofi, LionTrust, Artemis, River and Mercantile, Somerset Capital Management and AllGoodFun. 

For further information please visit www.sailingroundtheisland.williamchanter.co.uk and to make a donation please visit http://www.justgiving.com/RTI4T1

You may have seen some media coverage about a new discovery by diabetes researchers that may lead to new treatments for diabetes. Some of the reporting has been a bit confusing, so this article lays out the facts of the research and how the findings may one day be exploited to help people living with diabetes.

The story comes from a new research study published by a research group based in Harvard University in the USA. This group, led by Professor Doug Melton, focuses on trying to understand how the insulin-producing beta cells in the pancreas grow, develop and regenerate, and how this process is disrupted in people with diabetes.

The research team were investigating how the body manages to increase the number of insulin producing beta cells in individuals without diabetes but where there is a greater need for insulin than usual, such as during pregnancy, or in individuals with a high carbohydrate intake. In the course of this research, the team identified a gene which is not normally switched on in the body. By following this lead, they discovered that the new gene made a hormone, and that this hormone could trigger beta cells to grow and divide at a vastly increased rate in mice.

For many years scientists have been struggling to understand how the healthy body regulates the number of beta cells it has in order to cope with the body’s metabolic demands. This new discovery opens a whole new avenue of research for scientists trying to uncover ways to make new beta cells in people who do not have enough.

Although the bulk of the studies that have led up to this discovery have been conducted with mice, the team have discovered that the gene for betatrophin does exist in humans, so it is likely that this mechanism is also at play in people. However the research team, and the majority of the press coverage, has been careful to highlight that considerably more research needs to be conducted before we can see if betatrophin could be used to trigger new beta cell growth in people.

You may have been surprised to see the headlines focusing on the potential benefits of betatrophin in treating type 2 diabetes, as beta cell replication is a core goal of JDRF’s cure research programme.

The reason reports have focused on the application of the discovery in type 2 diabetes is that betatrophin, given on its own, may be enough to help people with type 2 diabetes regain control over their glucose levels. This is because their bodies would then be able to produce enough insulin to meets its needs.

In type 1 diabetes, the picture is not so straightforward, as restoring numbers of beta cells in the body is only part of the problem – there must also be a way to stop the body's own immune system destroying beta cells.  So for a treatment arising from this research to work for people with type 1 diabetes it would need to be coupled with another treatment to prevent this immune destruction from wiping out the new cells.

This is why JDRF’s research strategy emphasises finding solutions to both these challenges, so that in the future combined therapy approaches may be able to provide a full biological cure for type 1 diabetes.

JDRF funds over 25 projects, just like this one, in the UK every year. Each project brings us one step closer to our ultimate goal of curing type 1 diabetes. You can help us continue our important work by making a donation now.

Andy Richardson wants the world to know that living with type 1 diabetes isn't holding him back.

And he's in a great position to show it – competing in one of Formula 1's junior categories, the British Formula Ford Championship.

Andy's rise from karting to the higher levels of motor racing was put on hold when he was diagnosed with type 1 diabetes in late 2010, after experiencing excessive thirst and weight loss. After diagnosis, he was forced to take time out from competing, while he learned how to manage his condition through daily insulin injections.

But now Andy, who is 21 years old and from Lincolnshire, is back on the racing track. Furthermore, his powerful Formula Ford racing car has been emblazoned with the JDRF logo – demonstrating his commitment to all those who live with the condition.

The logo certainly hasn’t harmed his luck. Competing at Thruxton race circuit in Hampshire on the Bank Holiday weekend, he achieved two podium finishes, crossing the line in second place in race one, and coming third in race three.

Andy admits that competing and living with type 1 diabetes does bring certain challenges.

He said:

'I don't eat and inject too close to the start of a race because I don't want it to affect my blood glucose levels when I'm behind the wheel. However, due to the intensive and adrenaline-fuelled nature of single seaters such as Formula Ford, I will boost my blood sugars with sugary snacks prior to a race. I have a routine of checking my blood glucose levels regularly in the lead up to the race. Type 1 diabetes doesn't have to limit you in your life. I want to prove that to everyone.'

Michael Connellan at JDRF said:

'We are so thankful to Andy for the phenomenal gesture of placing the JDRF name on his racing car. This will help raise awareness of the condition, and of JDRF’s mission to treat, prevent and cure type 1 diabetes. He is a superb role model for young people who have been diagnosed with the condition.'

Ford is a long-term supporter of JDRF – learn more on the JDRF Corporate partners page.

Follow Andy on Twitter:
@AndyRichardson0 

Abbott Diabetes Care has issued a safety notice for its FreeStyle InsuLinx blood glucose meters.

The company has announced that at extremely high blood glucose levels of 56.8 mmol/L and above, the FreeStyle InsuLinx meter will display and store in memory an inaccurate low result.

This could cause a delay in identification and treatment of high blood glucose levels, or incorrect treatment may be recommended by the insulin calculator, if this feature is enabled on the meter. The likelihood of experiencing such extremely high blood glucose levels is rare, but this could lead to serious injury. Those who experience symptoms which are not consistent with their readings should contact their healthcare professional and follow his or her treatment advice. 

To address the issue, an online step-by-step process has been given, that users should follow to immediately update their meter’s software. This is available at www.freestyleinsulinx.com/swupdate

Those who are affected can alternatively call 0800 088 5521.

The company announced the move on 15 April. There are no other Abbott Diabetes Care products affected by the issue.

Some people will always go the extra mile for charity but Gavin Griffiths, a 21-year-old from Kent, is going even further. He has created the 30/30 challenge – running 30 miles every day for 30 days – with Sir Steve Redgrave MBE, boxing champion David Haye and Sir Geoff Hurst MBE all showing their support.

Gavin will be donning running shoes on Saturday 27 April to start the epic journey for JDRF and Diabetes UK. The journey will see Gavin run an incredible 30 miles every day for 30 days across the length and breadth of the UK, running approximately seven hours a day. Starting in John O’Groats, Gavin will take in the sights of Scotland, touching on the North East, the North, running through the Midlands, then the South West to complete his journey at Land’s End.

In January 2000, Gavin was diagnosed with type 1 diabetes. He was eight years old. Over the past five years he has become an ultra-marathon runner, completing distances including the 77 mile perimeter of the Isle of Wight and running the 44 mile trip from Hastings to Brighton.

Last summer Gavin was an Olympic torchbearer at Westgate-on-Sea and will bring the torch on his 30/30 adventure. He said:

'I’ve created the GBR 30/30 challenge, running 30 miles for 30 days, to prove that just because I have been diagnosed with type 1 diabetes it doesn’t stop me achieving anything in life. Type 1 diabetes is a life-long condition but I’ll continue to remain positive and live my life to the full. Please support me in my challenge and help raise lots of money for two great charities JDRF and Diabetes UK.'

The challenge is being supported by GBR Nutrition and GlucoMen with support from the MyWhereAbouts app that will be providing Gavin a phone which will provide updates on his location, pace and miles covered each day through to supporters. 

Celebrity supporters include Sir Steve Redgrave MBE who has type 2 diabetes. Steve said:

'I would like to wish Gavin the best of luck with this sponsored run for Diabetes UK and JDRF UK, charities close to my heart. This is indeed a huge challenge and I hope Gavin succeeds as I am sure that he will do.'

Boxer David Haye said:

'I just want to wish you the best of luck in your upcoming challenge. It is a momentous task you are going out to achieve – 30 miles for 30 days! I wouldn’t even take on running a marathon as my body probably wouldn’t be able to hack it, so what you’re putting yourself through as someone with type 1 diabetes is absolutely amazing. This is me David Haye wishing you Gav all the luck in the world, go out there and do your thing!'

Legend Sir Geoff Hurst MBE said:

'I just want to wish you all the very best in your 30/30 challenge, I mean 30 miles a day for 30 days that’s fantastic! I wouldn’t like to run it any month of the year! All the very best for two great charities, and succeed! Good luck.'

Please support the challenge by donating online or by text message: enter the code GBRJ60 for JDRF or GBRD60 for Diabetes UK followed by your donation to 70070 i.e. GBRJ60 £10.

Visit www.diathlete.org for further information on Gavin's challenge.

View Gavin's itinerary »

Follow Gavin on Facebook
GavGbr3030 

Follow Gavin on Twitter
@GBR3030

Watch Gavin's promotional video

JDRF has teamed up with Blossoms Healthcare to offer one lucky supporter two tickets* to the international smash hit theatre show Stomp at the Ambassadors Theatre, including a night’s stay in a central London hotel.

Originating in Brighton back in 1991, Stomp has since grown into a global stage phenomenon that has won numerous prestigious awards. The show combines theatre, dance, comedy and percussion using everyday objects to create a unique physical theatre performance.

BBC London said of Stomp: 

 'the unique musicality and movement… lies in the range of everyday objects it employs to achieve its effects: this is a show that finds sound in manipulating everything from broomsticks to matchboxes, toilet plungers to plastic carrier bags, cigarette lighters to water cooler containers.'

JDRF is very grateful for the support of Stomp and Blossoms Healthcare, the private medical service for individuals and businesses, for providing this exciting prize.

Blossoms Healthcare is a new supporter of JDRF; providing competition prizes for our donors, sponsoring JDRF events and introducing us to new and exciting potential supporters.

How to enter

To be in with a chance of winning this fantastic prize, ‘like’ the JDRF UK Facebook page. A winner will be randomly selected from everyone who 'likes' the page between 19 April and 1 June 2013, when the competition closes. The winner will be announced shortly after the closing date.

Terms and conditions

Please note that the theatre tickets are limited to Monday, Thursday and Sunday performances and should be booked in advance to avoid disappointment.

If you have already liked the JDRF UK Facebook page, or do not use Facebook, you can enter this competition by emailing info@jdrf.org.uk to let us know that you would like to be entered into the draw.

• The closing date is 1st June 2013.
• Only one entry per person.
• Competition is only open to UK residents aged 18 years or over.
• Winner will be selected at random after the closing date by an independent judge from all entries received. The judge's decision is final and no correspondence will be entered into.
• Winner will be notified in the first instance by email or via Facebook within 1 week of the closing date. Following such notification, the winner will be required to enter into correspondence with JDRF in order to redeem the prize.
• If JDRF cannot: (i) contact the winner (via the details provided at the date of entry) within a reasonable period of time (14 days after first attempt at contact); or (ii) the winner does not respond within 14 days of notification that they have won the Prize, JDRF reserves the right to re-draw a winner and thereafter until a winner on these terms is found.

JDRF is paying its respects to Professor Harry Keen, a leading light of diabetes research and care, who has died this month (1925 – 2013).

Harry was an exceptional research scientist who helped to shape the understanding of both type 1 and type 2 diabetes that we have today. He inspired our current generation of leading diabetologists.

His body of work included the highly influential Bedford Survey in the 1960s. Notions of diabetes and its complications in that decade were, in Harry’s words, 'pretty primitive.' His survey, screening the whole adult population of Bedford for undiagnosed diabetes, helped scientists to grasp the full significance of blood glucose levels in relation to type 1 and type 2.

He was also a pioneer of insulin pump therapy, trialling an early pump device on a patient, Winifred Vincent, and seeing major improvements in her blood glucose control.

His career roles included Professor of Human Metabolism at Guy's Hospital Medical School, and following retirement he became Professor Emeritus at Guy’s Hospital Campus of King’s College London School of Medicine. He was an Honorary President of the International Diabetes Federation and was heavily involved with a number of other diabetes organisations and charities.

Karen Addington, Chief Executive of JDRF, said: 'On behalf of all at JDRF, I would like to convey our condolences to Professor Keen’s family. Harry was a truly great clinician and researcher. His work in the diabetes field, examining how we can prevent, treat and eventually cure type 1, is deserving of deep admiration. On a personal level I had a huge amount of respect for Harry. He will be greatly missed.'

To read more about Professor Keen’s work please read his interview with JDRF's magazine back in 2008.

Bidford on Avon resident Carl James, 43, is dedicating the next six months of his life to complete eight amazing challenges after months of intense training. Carl is taking on his challenge to raise funds for JDRF, after his son Toby, a pupil at Temple Grafton C of E Primary School, was diagnosed with type 1 diabetes in 2008, when he was just 17 months old. 

Carl often went the extra mile by fundraising for JDRF following Toby’s diagnosis. But this is his most epic journey yet - enduring eight challenges across the country. Carl will begin by pounding the streets of London, as his challenge kicks off with the Virgin London Marathon, on Sunday 21 April.

Celebrity adventurer and broadcaster Mark Beaumont is also running the London Marathon for JDRF this year – and has given Carl his backing. He said:

'People living with type 1 diabetes face some very tough challenges. The condition stays with them for life and can have a big effect upon both them and their family. That’s why taking on a tough sporting challenge like the Virgin London Marathon to raise money for JDRF is a fantastic thing to do. I congratulate each and every person who is doing so.'

Carl said:

'When Toby was diagnosed with type 1, I made myself a commitment to fundraise for JDRF every other year, extending the physical challenges every time. I hope that by pushing myself harder and harder it will raise awareness for type 1 diabetes and I’m determined to raise as much money for JDRF as I can. So I would encourage everyone to make a donation, however big or small, to help a great cause.'

Carl’s other challenges include… 

The Dorney Olympic Triathlon, 26 May: Eton Dorney was the home of rowing and canoeing in the London 2012 Olympics – it was also where Carl completed his first triathlon. The Olympic distance is made up of a 1,500m open water swim, followed by a 40km bike ride and finally a 10km run.

Welsh 3,000s, 1 and 2 June: This daunting event involves covering 24 miles in 24 hours – including 13,000ft of ascent along the way, conquering all 15 of the Welsh mountains over 3,000ft.

South Cerney Sprint Triathlon, 15 June: This event involves a 750m open water swim, a 20km bike ride and a 5km run.

Land’s End to Dover cycle, 1 – 5 July: For his biggest challenge, Carl and six amazing friends will ride 400 miles in four days. The event consists of Land’s End to Newton Abbot on day one, on to Poole for day two, then to Brighton on day three and finally on day four crossing the finish line in Dover.

London Olympic Triathlon, 28 July: Another 1,500m swim, 40km pedal and 10km run this time as part of the UK’s largest triathlon around the iconic Royal Docks in London.

Lyke Wake Walk, 31 August: This route means a lot to Carl as his father completed it as a Scout. It will be Carl’s fourth crossing of the 44 mile non-stop route, which extends across the North York Moors from Osmotherley to Ravenscar.

HSBC Olympic Triathlon, 15 September: To end the year Carl is heading back to Eton Dorney for his fourth triathlon of the year – a 1,500m open water swim, a 40km bike ride, and a 10km run.

Jon Medcraft, Senior Challenge Events Fundraiser at JDRF, said:

'We are delighted that Carl has decided to raise vital funds for JDRF, which will help the charity to back research into finding the cure for type 1 diabetes. We look forward to cheering him on during the events and wish him every success.'

Visit Carl's JustGiving page to follow his progress throughout the challenge or donate, or follow Carl on Facebook.

“Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes” (DILT1D)

JDRF funded researchers at Addenbrooke’s Hospital Cambridge and the University of Cambridge have recently begun a clinical trial that aims to develop a potential new treatment for people with recently diagnosed type 1 diabetes.

The study is investigating an existing drug called aldesleukin. The team will look at whether this medication can restore balance to the immune system in recently diagnosed type 1 diabetes and if so, what dose of the drug is required for best results.

Led by Dr Frank Waldron-Lynch at the JDRF/Wellcome Trust Diabetes and Inflammation Laboratory, the study is being carried out in the Wellcome Trust Clinical Research Facility at Addenbrooke’s Hospital, Cambridge and NIHR Clinical Trials Unit. The team aims to recruit 40 patients from all over the UK who have been diagnosed with type 1 diabetes in the last two years.

The trial follows on from other research by the laboratory group which is led by Professor John Todd.  The members of this lab are investigating the underlying causes of type 1 diabetes and have shown how variations of certain genes can alter pathways involved in the immune system. One of the pathways affected is the interleukin-2 pathway and the trial will test if aldesleukin (which is also called interleukin-2) can restore balance to the immune system.

Professor John Todd commented,  “Our studies of how type 1 diabetes is inherited and how the diabetes genes cause disease have led us to investigate the possibility that the injection of very small doses of this drug might strengthen the regulation of the immune system and slow up destruction of the insulin-producing cells in the pancreas.”

Dr Frank Waldron-Lynch, Chief Investigator for the study commented “The DILT1D clinical trial is the first step on a clinical development program to advance interleukin-2 as a treatment for recently diagnosed type 1 diabetes. We are keen to have the type 1 diabetes community help us with this new clinical research”

To find out more about what participation involves please contact a member of the team by email: DILT1D@cimr.cam.ac.uk or telephone 01223 762327. You can also find out more information on their website or follow them on facebook and twitter.

Father-of-three Roddy Riddle, from Inverness, is to become the first ever person with type 1 diabetes to take part in the gruelling six-day, 156 mile Marathon Des Sables challenge in the Sahara.

Roddy, a former international road cyclist, was diagnosed with type 1 diabetes five years ago and wanted to compete in the toughest race in the world to show that type 1 doesn’t have to be something which holds you back. Roddy hopes to show others with the condition, who can lose confidence when it comes to exercise, that they can live normal active lives. At the same time he wants to raise awareness of type 1 diabetes and raise vital funds for JDRF and Diabetes UK.

Roddy said:

“The commitment and dedication that comes from the people at JDRF is unbelievable. What makes the connection even closer is many of the people at JDRF live with type 1 themselves.”

The Inverness iron man will begin the Marathon Des Sables challenge on 7 April and will finish on 13 April. The race takes place across one of the harshest regions on earth – the Sahara desert, which reaches temperatures of up to 50°C. The race is the equivalent of running six marathons in six days. It will be essential for Roddy to ensure his blood glucose levels don’t slip dangerously low or too high. To assist him with this he will run with an insulin pump and a continuous glucose monitor (CGM).

Roddy kick-started his fundraising for JDRF and Diabetes UK with an auction dinner and dance on Saturday 2 February. It raised an amazing £17,765 which was split between both charities. Two of the top prizes on the evening were Marathon Des Sables replica tops signed by Sir Chris Hoy, Sir Bradley Wiggins and Sir Steve Redgrave – three British Olympians!

On the night a supportive video was played featuring Caroline Hellicar, JDRF's Director of Fundraising – scroll down to watch the video.

On his return, Roddy will be at the Eden Court Theatre, Inverness, sharing his experiences. Joining Roddy in conversation will be Moray Firth Radio presenter and newspaper columnist Nicky Marr. Expect tales of scorpions and bivouacs, sand storms and insulin pumps. Tickets are £15 with all proceeds going to JDRF and Diabetes UK – find out more about the event and buy tickets

JDRF wishes Roddy the best of luck with his incredible challenge, we will be thinking of him every day of the race. 
You can support Roddy in the toughest race on earth by sponsoring him »

Watch JDRF Director of Fundraising Caroline Hellicar's message of support for Roddy

On 23 March at 6.30pm, over 280 guests arrived at the Marcliffe Hotel and Spa for the eighth JDRF Gala Ball in Aberdeen. Eight hours later the last guests were leaving, with an incredible £136,000 raised for JDRF.

The ball had a Shanghai theme, starting with a drinks reception with Shanghai Sling cocktails. Guests then entered the stunning ballroom, decked out in gold and red with Chinese lanterns hanging from the ceiling, where they were welcomed by host Dougie Donnelly. 11 year old Rachael Pyper then gave a moving speech about how she has coped with life with type 1 since being diagnosed at the age of 10.

A fortune cookie table game was followed by a delicious Chinese-inspired dinner. The star raffle prizes, including a Kindle Fire HD, £200 M&S vouchers and a Samsung Galaxy Tablet, were drawn and then the live auction was underway.  For Lot 13, Professor John Petrie spoke about the vital research he is doing around heart disease and type 1 diabetes at the University of Glasgow, before inviting guests to pledge their support to his research project. 

By the end of the night last year’s total of £112,000 was smashed, with the final figure reaching £136,000. This money will help JDRF to fund vital research to find the cure for type 1 diabetes.

Catriona Morrice, Regional Fundraiser for JDRF Scotland, said:

‘JDRF Scotland would like to thank everyone who attended the Shanghai Ball, kindly donated prizes and volunteered their time on the evening. Together with the hard work of the ball committee in organising the event, everyone helped to make the evening such a great success. A huge thank you to our corporate sponsors whose support and generosity was invaluable on the night. We really would not have been able to achieve any of this without everyone’s support.’

We look forward to seeing you at the Aberdeen Gala Ball in 2014!

Tickets are still available for the Shanghai Ball in Edinburgh on 8 June 2013. Find out more and purchase tickets »

Professor Peter Jones from King’s College London has recently been awarded JDRF funding for a new islet encapsulation project.

Professor Jones and his team are working on a method of encapsulating islets called nano-encapsulation. This involves wrapping islets in a thinner material than other encapsulation research strategies are using.

A thinner encapsulation material will mean that the cells can be transplanted into a vein next to the liver called the portal vein. This is where cells are placed in the current islet transplant protocol. The coating used by other experimental encapsulation techniques is thicker so the cells are too bulky to fit in the portal vein, which means they must be transplanted within the abdomen which may be less effective.

Another benefit of nano-encapsulation is that drugs can be incorporated in the casing that could help more islet cells survive after transplant. This could make islet transplants more efficient and mean that fewer cells would need to be transplanted.

In this project Professor Jones and his team will test their nano-encapsulation system in mice to determine if it can protect islet cells from the immune attack and compare it to other encapsulation systems to see if it is more effective.

Encapsulating islet cells or wrapping them in a protective casing before they are transplanted would help to protect them from the immune system. The casing has tiny holes in it to let insulin out and nutrients in but the cells in the immune system which are a bit larger, are not able to get in to attack the cells.

Dr Maebh Kelly, Research Communication Officer at JDRF said, ’Perfecting islet encapsulation would be a great way to help people with type 1 produce their own insulin while providing protection from the immune system. Nano-encapsulation is an exciting prospect and we look forward to seeing the results of Professor Jones’ study’  

JDRF is calling on people in Cardiff and surrounding areas to join in our Type 1 Discovery Day on Saturday 13 April 2013. The event is an opportunity to learn more about the condition and the work of JDRF.

The JDRF team will be on hand to answer questions. There will also be a talk from Dr Garry Dolton from Cardiff University School of Medicine’s Department of Infection, Immunity and Biochemistry. Dr Dolton will be talking about his research into why certain T-cells attack insulin-producing cells and will be answering questions on the day.

Hannah Jarrett (pictured),16, a JDRF T1 Youth Ambassador from Bridgend will also be talking about living with type 1 diabetes. Hannah was diagnosed two weeks before her 11th birthday. Since being diagnosed, she has endured over 9,000 plus blood glucose tests and over 6,000 injections. She now receives insulin through a pump.

Hannah was a torchbearer at the 2012 Olympics and is dedicated to raising awareness of type 1 diabetes. She said:

'I’m really pleased that I’m able to help raise awareness of type 1 diabetes. JDRF is a great charity and I encourage my family, friends and even strangers to support such a great cause. Finding the cure for type 1 would mean the world, not only to me but my family too, and I know JDRF is dedicated to finding the cure.'

Danielle Angell, JDRF Regional Fundraiser for Wales, said:

'We are looking forward to the up and coming JDRF Type 1 Discovery Day in Cardiff. Whether you are a parent of a child who has type 1, have the condition yourself, have recently been diagnosed or have had the condition for years – the day is aimed to be fun and educational for all in the type 1 community.'

JDRF has issued a special thank you to the Medical Detection Dogs team which will also be there on the day to talk about hypo alert dogs.

This year’s event will be held at the Maldron Hotel, St Mary Street, Cardiff, CF10 1GD between 9.45am – 12.30pm. Find out more about the event and book online, or book by phone on 07531 901186 or by email at dangell@jdrf.org.uk.

LifeScan, the manufacturer of OneTouch Verio Meters, has today announced a voluntary recall and replacement of its OneTouch Verio Pro, OneTouch Verio IQ, and OneTouch Verio Pro+ blood glucose meters.

At extremely high blood glucose levels of 56.8 mmol/L and above, the meters do not operate as intended. This could lead to incorrect treatment or delay proper treatment of extreme hyperglycemia, potentially resulting in serious injury.

The company announced the move on 25 March.

If this affects you, learn more at http://www.lifescan.co.uk/recall

We are delighted to announce that the celebrity adventurer Mark Beaumont will be taking part in this year's Virgin London Marathon on behalf of JDRF.

Mark is a true adventurer. He was previously the world record holder for solo circumnavigation of the world by bike. This journey was made into a BBC documentary, ‘The Man Who Cycled The World,' and a book that has sold more than 100,000 copies worldwide.

In 2010, Mark completed a 13,000 cycle down the length of the Americas, from Alaska to Tierra del Fuego, also climbing the two highest peaks in North and South America respectively. This was also made into a BBC documentary and book. His many other adventures have included rowing to the 1996 location of the Magnetic North Pole to highlight the effects of climate change.

Mark joins us as a Corporate Ambassador for LDC, which has been involved with JDRF since 2007, raising more than £500,000 for the charity. The Virgin London Marathon takes place on 21 April 2013. 

Mark said:

'I'm very proud and really looking forward to be running this year's Virgin London Marathon for JDRF alongside my colleagues from LDC as part of the charity’s 196-strong team. Our aim is to raise £500,000 for research into type 1 diabetes. All of the LDC corporate team and my fellow JDRF runners seem to be training hard and I am sure will be a great inspiration on the day. Despite all the endurance challenges that I have completed, this will be my first marathon!'

If you're feeling inspired and would like to take on a challenge for JDRF, visit our Events section and get involved »

Guests are to be treated to a magical Chinese-style ball staged in Aberdeen to raise funds for JDRF. The Fifth Business is for the fourth year running sponsoring JDRF’s Shanghai Ball on Saturday 23 March. 

The 2013 ball will be held at the Marcliffe Hotel & Spa in Pitfodels, Aberdeen. Scottish golf broadcaster and compere, Dougie Donnelly, will be there to encourage the guests to give generously. 

Those attending will be treated to an evening of dining and live music with both a live and silent auction. They will get the opportunity to learn more about the research that JDRF supports, while enjoying the exciting Chinese theme.

Last year’s ball raised an incredible £112,000 and the JDRF team hopes to trump that figure this year. The funds raised will support research to cure, treat and prevent type 1 diabetes - which affects more than 28,500 people in Scotland alone. Male Scots are more likely to have the condition than females, with 56 per cent of those living with the condition in Scotland being men and boys.

The Fifth Business, which is excited to be part of the occasion, is a long-term JDRF supporter. The company provides JDRF with graphic design, offers support at major events, and has continuously fundraised on its behalf down the years.

Enda Logan is Chief Executive of The Fifth Business and a member of the Scottish Development Group – a collective of leading professionals within Scottish industry that aims to support local charities such as JDRF in Scotland. He said:

'This is sure to be a night to remember and another great opportunity to support a very important cause. The Fifth Business will continue to support JDRF in all its future activities. We wish the team the best of luck.'

Alastair Brookes, JDRF’s Development Manager for Scotland, said:

'As always we are entirely grateful to The Fifth Business for their help for the event but also for their support across the years. Without the support of local businesses and supporters, we wouldn’t be able to fund the research to help find the cure. Thanks to everyone who has made this possible and here’s to a great night – please remember to dig deep.'

Edinburgh will also play host to a JDRF Shanghai Ball on 8 June 2013. Click here to find out more.

JDRF has welcomed the appointment of Dr Jonathan Valabhji as the new National Clinical Director for obesity and diabetes for England.

Karen Addington, Chief Executive of JDRF, said: “Dr Valabhji’s background as a clinician specialising in diabetes is particularly welcome. It means we can be hopeful that he will not allow the UK’s response to diabetes to be disproportionately dominated by the anti-obesity agenda.

“The anti-obesity agenda risks clouding the crucial fact that for many thousands of people with type 1 and type 2 diabetes, lifestyle was not an influencing factor. A focus on obesity supports a 'blame culture', and undermines efforts to develop better treatment and ultimately cure the conditions. 

“Type 1 diabetes is an autoimmune condition and is not caused by lifestyle factors such as diet and exercise. Type 2 diabetes is sometimes linked to diet and exercise – but not always. The need for the UK to tackle its obesity problem must not obscure the equal need for the Government to back greater investment in research to cure, prevent and develop better treatment for type 1 and type 2 diabetes.” 

The number of people developing type 1 is rising each year, as is the number of people developing many other autoimmune conditions. Researchers believe that the number of new cases of autoimmune diseases is rising so quickly that it must be in response to environmental factors.

In two new studies published recently in the prestigious journal Nature, researchers have found that salt may have a role to play in autoimmune conditions.

In the first study the researchers investigated why some people produced high quantities of TH17 cells which are involved in autoimmunity. While investigating patterns associated with changing levels of TH17 cells, they found that a gene called SGK1 correlated with levels of TH17 cells. SGK1 is usually involved in processing salt in the body so is associated with higher levels of salt. While SGK1 is activated in response to salt, it appears to increase the number of TH17 cells as a side effect.

The second study validated these findings, by adding salt to cells in the lab. They found that when more salt was added to cells, more TH17 cells were produced. In addition to that, feeding mice with multiple sclerosis a high salt diet accelerated the condition.

Dr Maebh Kelly, Research Communication Officer at JDRF commented, ‘This is an interesting new avenue of research into the cause of autoimmune conditions but it is much too early to say whether or not salt has a role in the development of type 1 diabetes. There are already many known implications of a high salt diet such as high blood pressure which is why the NHS has issued guidance on recommended daily salt intake’

Read the NHS guidelines on salt intake 

JDRF-funded researchers in Zurich, Switzerland have discovered that a single gene variation could be involved in the development of type 1.

The lead researcher, Dr Marc Donath, started this project when he discovered one of his patients had an unusually strong family history of type 1.  Genetic testing revealed that the family members who had type 1 had a particular variation in a gene called SIRT1. The family members without type 1 did not have this gene variation.

Further investigation revealed that in mice with this gene variation, beta cells produced more chemicals that had a destructive effect on cell survival. In addition, the researchers showed that switching off the SIRT1 gene in mice increased their risk of developing type 1.

Many genes have been shown to increase the risk of developing type 1 but this is the first time a single variation of a gene has been found to lead directly to type 1. This variation of the SIRT1 gene is expected to be very rare and will not be the direct cause of many cases of type 1.

However the discovery of the role of the SIRT1 gene in beta cell survival will give researchers new clues about how type 1 develops. The researchers speculate that beta cell death and dysfunction caused by SIRT1 could prime the immune system to identify and attack them.

Dr Maebh Kelly, Research Communication Officer at JDRF said, ‘There is growing evidence that abnormal beta cells may have a role in the development of type 1 and this study adds to that argument. Preventing or reversing beta cell dysfunction may help to delay the onset of type 1, so learning more about what happens to beta cells in the early stages of the condition is one way for researchers to gain clues as to how to protect these vital cells.’

JDRF supporter George Kirkpatrick, 21, is to spend his Easter weekend on a gruelling challenge for charity after months of intense training. George and his friend Rory McGrath are to complete an epic 125-mile kayak in as close to 24 hours as possible, in the world-renowned Devizes to Westminster International Canoe Marathon. 

The event starts in Devizes, Wiltshire, on 30 March, and finishes 24 hours later on 31 March on the Thames in front of the Houses of Parliament. George and Rory will complete the adventure in aid of JDRF.

 George, an Oxford Brookes University sports scholar, was diagnosed with type 1 diabetes when he was just four years old, in April 1996. Since diagnosis, he has had more than 29,000 insulin injections and has completed over 35,000 blood glucose tests in order to manage his type 1 diabetes. To make matters worse, George’s younger brother, Gus, was also diagnosed with the condition in September 2009 aged 13 years old.

 George is a dedicated JDRF supporter and is keen to raise awareness of the condition. The challenge will see the pair kayak along the Kennett and Avon Canal to Reading, before reaching the Thames and completing the final section on the tidal part of the river in to London.

George isn’t shy of a challenge. To mark the 15th anniversary of his diagnosis, George ran the 2010 London Marathon and raised over £50,000. This is the largest sum an individual has ever raised for JDRF by running the Marathon and George is immensely keen to complete his up-and-coming challenge in a similar fashion and hopes to match his last fundraising efforts.

 George said: “The condition has hit our family like nothing else and has really inspired me to make a difference. Gus and I owe a debt of gratitude that we will never be able to repay to our long suffering family and friends, who have helped us through the ups and downs. This is our chance to make a difference and we are truly dedicated to helping JDRF find the cure for type 1 diabetes and raise awareness of the condition.”

 “I cannot stress enough the importance that every penny contributed will have towards finding the cure. It will make such a difference to me and the 400,000 other people with this chronic condition. It has such a big impact on them and their families.”

 Jon Medcraft, JDRF’s Senior Challenge Events Fundraiser said: “The Kirkpatrick family has always been firm supporters of JDRF and for that we are entirely grateful. George is an inspirational young man, who proves time and again that no matter what the challenge, nothing is impossible, from running the marathon to his latest kayaking event. I want to thank him and wish him and Rory every success. If you are keen on taking up an event challenge, like George, then JDRF has an event waiting for you.”

You can find more JDRF events here. 

To donate to George, Rory and JDRF please visit www.justgiving.com/kayakingtoacure

To follow George and Rory, please visit their blog: kayakingtoacure.blogspot.co.uk

The Diabetes Research Institute (DRI) in Florida recently announced details of a new device they are working on for the treatment of type 1 called the 'BioHub'.

The BioHub is a beta cell encapsulation device that is currently being developed through many different projects at the institute.  The research teams are working together to create a sponge-like structure that can house beta cells. The BioHub will create a 3D scaffold for beta cells which will ensure all the cells have equal access to the oxygen and nutrients they need to survive until they are connected to the body’s blood supply.  Spreading out the cells in this manner will make it easier for new blood vessels to form and nourish the cells, and consequently help more cells to survive after transplant.

The research team first aim to use the BioHub simply as means to improve the efficiency of beta cell transplant, by improving the cells’ survival, but they also believe that the BioHub will eventually be developed to a point where it can protect the cells from the immune system.

JDRF is currently funding research at the DRI that feed into this project, including a recently announced partnership with the Helmsley Charitable Trust. This partnership aims to develop new materials to protect transplanted cells from the immune system and to help more cells survive until they can get connected to the body’s blood supply.

Replacing the beta cells that have been lost in type 1 is the goal of many ‘cure’ therapies but there are still hurdles that need to be overcome to make this a reality. Currently there is no plentiful supply of beta cells for transplant and it is difficult to protect the transplanted cells from immune attack. JDRF supports a broad portfolio of research projects around the world testing different approaches that could resolve the problems associated with beta cell replacement.

Dr Maebh Kelly, Research Communication Officer at JDRF commented, ‘JDRF supports the research at the DRI and we work together on many projects. The BioHub is interesting as one of the problems with transplants at the moment is that many cells die shortly after the transplant. Methods to keep more cells alive until they can be connected to a blood supply will make a big difference in improving the success of transplants.’

Can stem cells be used to treat diabetic ulcers? A research team in Ireland are trying to find out.

The scientists, led by Professor Timothy O’Brien at the National University of Ireland in Galway, have been using stem cells that are taken from bone marrow (called mesenchymal stem cells) to help wounds or ulcers grow new blood vessels. This could allow the wounds to heal faster.

The stem cells can be taken from bone marrow and transferred onto a biological 'scaffold' that can be applied to the wound like a stem cell bandage. The researchers made lots of different versions of their bandages, with gradually increasing numbers of stem cells added to the scaffold. Working with diabetic rabbits (which develop ulcers in a similar way to humans) the team found that all versions of the bandages encouraged new blood vessels to grow in the affected area. But the bandages with the highest number of stem cells were found to be most effective in reducing the time it took for the wounds to heal.

In people with type 1, ulcers can take a long time to heal. This increases the risk of infections and if untreated can lead to more serious problems. One of the reasons ulcers can take a long time to heal in people with diabetes is that prolonged periods of high blood glucose levels can affect blood vessels and can reduce circulation to extremities (especially the feet).

Dr Maebh Kelly, Research Communications Officer at JDRF said, ‘This research shows the potential of stem cells to treat the complications of type 1.  Increasing the amount of blood vessels in the affected area would mean more oxygen and nutrients are available to help the body heal faster.’

The artificial pancreas team at the University of Cambridge have recently launched a new study with children aged between two and six years with type 1 diabetes. The aim of the study is to test the ability of the artificial pancreas to control blood glucose levels in younger children who are on much smaller total daily doses of insulin than older children and follows on from successful results in similar trials with older children and teenagers. Already, three children have participated in the study.

This is the first trial of the artificial pancreas system in such young children in Europe. The children who join the trial will be asked to spend two separate overnight stays in hospital (two- six weeks apart) under the constant supervision of nurses and doctors. As smaller children require very small doses of insulin, it may be more difficult for the artificial pancreas to ‘fine tune’ blood glucose levels while using such small volumes of insulin. To overcome this, the researchers will dilute the insulin in the pump on one of the visits and use standard insulin on the other visit to test if the system can perform more accurately with diluted insulin.

The team are currently hoping to study 12 children. To join the study participants must able to stay overnight in Cambridge on two separate occasions and must be currently registered at the Norwich, Ipswich, Peterborough, Cambridge or UCL hospitals. 

JDRF has been shortlisted for Charity of the Year at the JustGiving Awards 2013. Thank you to all our supporters and partners who intially nominated us then voted for us in the people's choice stage.

We are now at the final stage where three charities are judged by a JustGiving panel. The winner will be announced on Thursday 11 April at the awards ceremony in London. We will let you know how we get on!

Thanks again to everyone who got us this far, all we can do now is cross our fingers!

About the JustGiving Awards 2013

The JustGiving Awards are their way of saying congratulations to the outstanding individuals, teams and charities who together helped raise nearly £200 million through their JustGiving pages for good causes this year.

Why do we think we deserve this award?

Finding the cure for type 1 diabetes will not only dramatically improve the lives of those living with the condition themselves, it will also bring relief to worrying parents, family and friends. Type 1 diabetes is a lifelong chronic condition, which needs attention every day and night. A life without type 1 diabetes would mean an end to daily injections and finger-prick tests, which combined can take up to two hours every day.

No more worrying about long term complications such as nerve damage, blindness, limb amputations, heart disease and many others. Not having to experience hypo (low blood glucose) or hyper (high blood glucose) episodes, which are a daily occurrence for most and are a horrible and very dangerous experience.

The cure would also be economically beneficial, removing the huge financial burden of a cost of £1.9 billion to the UK annually. Current data estimates this could rise to £4.2 billion each year, an expense almost eradicated by the cure or better treatmentIn just 26 years, JDRF has pioneered, supported and funded some of the most innovative treatments allowing people with type 1 diabetes to live a normal and fulfilling life.

The cure is only a matter of time and funds, so we will continue to push for increased funding in type 1 research, in order to decrease the amount of time before the cure is found.

Some of the achievements in 2012 we are proud of

T1 Parliament

In April 2012, JDRF held our first Type 1 Parliament, a highly successful campaign in which 60 children and adults with type 1 met their MPs in Parliament, to gain their support for JDRF’s campaign for greater investment into research. This event attracted 55 MPs, including David Willets MP, Minister of State for Universities and Science.

JDRF President, Her Royal Highness The Duchess of Cornwall 

Her Royal Highness The Duchess of Cornwall agreed to become our President in June 2012. This five year commitment will put type 1 in the spotlight and demonstrate how this serious auto-immune condition is often overlooked. 

Research projects

One of the projects is the artificial pancreas, an exciting piece of technology that could do the job of a healthy pancreas. Using current technology (a continuous glucose monitor and insulin pump), we add an algorithm to produce an automated system which will help people with type 1 achieve better blood glucose control, and reduce the burden of diabetes care. Researchers are now running trials, allowing children to test the system at home for three weeks.

Some of our 2012 fundraising 

Art Antiques London Party in the Park

In June 2012, JDRF became sole beneficiary of the Art Antiques London Party in the Park event held in Kensington Gardens, and raised a ground breaking £485,000. Over 600 attendees enjoyed cocktails and canapés, followed by an exclusive dinner, acoustic performance by the Scissor Sisters and an impressive celebrity-based auction. 

The Virgin London Marathon

The Virgin London Marathon is always a highlight of the JDRF calendar, but 2012 was an exceptional record-breaking year; 195 JDRF runners successfully completed the 26.2 mile course (including 26 with type 1) raising over £535,000, the largest amount we have ever raised from the event. 

World Diabetes Day 2012

On Wednesday 14 November JDRF marked World Diabetes Day, an international day that engages millions of people worldwide in diabetes advocacy and awareness. To spread awareness and show support, iconic buildings around the UK were lit up in blue, including Clarence House, official residence of JDRF President HRH The Duchess of Cornwall, and 10 Downing Street. 

If you require any further information please contact kwood@jdrf.org.uk. 

On 8 March 2013, to coincide with International Women’s Day, Cathy Ferris from Aberdeen will be leading a dance jam as part of Global Nia 2013.  Nia is an exhilarating dance workout and Cathy’s class, in aid of JDRF, will take part alongside 42 classes in 18 different countries across the world. 

JDRF is committed to finding the cure for type 1 diabetes, improving the lives of people with type 1 until this happens.

Cathy chose JDRF as her beneficial charity, as close friend Mike Unger and Mike’s daughter Grace (pictured), nine, both have type 1 diabetes. Mike has been living with the condition for the past 31 years and Grace was diagnosed aged three years old.

Cathy said:

'I’m thrilled to bring Nia to Aberdeen.  Nia brings me so much joy, and now I have the honour of sharing it with my community, while benefiting JDRF.  I’m hoping to raise £450 and I would encourage people to come to the class or donate online to help JDRF one day find the cure for type 1 diabetes.'

The money raised will help to support vital research into finding the cure for type 1 diabetes and its complications. The chronic condition can strike suddenly and without warning. 

Get involved

The Nia class will be on Friday 8 March 2013, 10 - 11.15am at His Majesty’s Theatre, Aberdeen. Click here to find out more about the event »

If you would like to sponsor Cathy please visit http://www.justgiving.com/Cathy-Ferris

A report published on 23 February by NHS Diabetes, the Society for Chiropodists & Podiatrists and Diabetes UK highlights that up to 80 per cent of foot amputations among those living with diabetes could be avoided if care improved. Over £119 million is spent each year on diabetes-related amputations within the NHS in England, and it is projected that the number of amputations will rise to 7,000 a year by 2014/15 if action is not taken.

Having an annual foot examination is one of the nine key annual tests recommended by the National Institute for Health and Clinical Excellence (NICE) for people with diabetes.

But results from the National Diabetes Audit 2011-12 showed that only 38.5 per cent of people in England and Wales with type 1 diabetes were receiving all nine NICE recommended checks, and in people under 55 this figure was even lower with only 33.1 per cent receiving all recommended checks.

Only 71 per cent of people with type 1 aged over 55, and only 66 per cent of people aged under 55, received an annual foot examination.

Early detection of the neuropathy (nerve damage) that can lead to foot ulcers is crucial to preventing amputations. Through our research programme, we are funding a project by Professor Rayaz Malik at the University of Manchester to develop a new system that can detect the early signs of neuropathy. This technology which scans the nerves in the eye is a quick, painless and easy way to screen people for the early signs. Improved screening methods like this should lead to more regular neuropathy tests for people with both type 1 and type 2 diabetes.

Karen Addington, Chief Executive of JDRF, said: “It is appalling that people with type 1 diabetes still face the risk of amputation because they are not receiving all the checks recommended by NICE. This new report is worrying for anyone with type 1 diabetes, or who has a child or loved one living with the condition. It highlights once again why increased investment in research to cure, treat and prevent type 1 diabetes and its complications, and access to the treatments that come from this research, is so vital.'

JDRF and the California Institute for Regenerative Medicine (CIRM) have promised more funding to help California based biotech company Viacyte develop a new stem cell therapy for type 1.

Viacyte’s product aims to use stem cells to replace the beta cells which are missing in type 1. While many stem cell therapies aim to turn the stem cells into fully mature insulin producing beta cells before transplant, Viacyte is trying to direct stem cells to become immature pancreatic hormone cells that cannot yet produce insulin.

The immature hormone cells are then transplanted into the body where the chemical signals in the pancreas will turn them into fully mature insulin producing cells.

In addition, the transplanted cells will be encapsulated in a device that keeps them protected from the immune system but allows oxygen and glucose in and insulin out. In this way they will be able to work as normal without being destroyed by the immune system.

Current cell therapies such as islet transplants are limited by the severe lack of donor islet cells. This product, by using stem cells rather than tissue form organ donors could overcome this hurdle. Furthermore, packaging the cells in a device that creates a physical barrier around the cells has the potential to protect the transplanted cells from immune rejection, and may eliminate the need for chronic immunosuppressive drugs.

Dr Maebh Kelly, Research Communication Officer at JDRF said, ‘JDRF is pleased to continue working with CIRM and ViaCyte on this innovative technology. Viacyte's product is exciting as it simultaneously tackles the two main problems associated with beta cell replacement therapies, lack of transplantable cells and the threat of the immune system.' 

Progress and promise in stem cell research

Local mum Rachel Deacon, from Warsash, led a fundraising initiative which saw JDRF, the type 1 diabetes charity receive over £3,000 from the local Co-Op store.

Rachel, a team member at the store, knows the importance of raising money for JDRF, which funds research to find the cure, treat and prevent type 1 diabetes. One of the 29,000 UK children who lives with the condition is her five-year old son, Charlie, who was diagnosed at just two years old.

At the time, Rachel noticed a change in Charlie, who is now a pupil at Hook- with-Warsash C. of E. Academy, he was tired, constantly thirsty and going to the toilet more than usual – all of which are symptoms of the condition. Rachel took Charlie to their local GP and was transferred to Queen Alexandra Hospital, Portsmouth, where the auto-immune condition type 1 diabetes was diagnosed.

 In order to manage Charlie’s type 1, he receives insulin via injections. He has to constantly test his blood glucose levels by doing finger prick tests, up to five times a day, and has to carb-count everything he eats.

JDRF was named Warsash Co-Op’s charity of the year 2012 and the team pulled out all the stops to raise funds from collection boxes, book sales and running the Great South Run. The store manager, George Howarth, even completed the North Dorset Village marathon, all to raise awareness of the life-changing condition.

Rachel said; "I was delighted that we were able to raise so much money for JDRF. They have provided a lot of support since Charlie was diagnosed and we are always keen to give back in any way that we can. I was thrilled that I was able to get the support from my work colleagues and our Co-Op customers. A huge thank you to everyone that supported us!"

Nikki Gerrard, Senior Fundraiser for Southampton said: "Thanks so much to Rachel and her dedicated team. Our supporters are the heart of the charity and we rely on people like Rachel to help raise awareness and funds. Thank you to each and every one of the Co-Op’s staff and customers who dug deep for the cure."

The global JDRF family has been deeply saddened to hear of the passing of Carol Lurie. She and her husband Erwin, together with Lee Ducat and a select few passionate parents founded JDRF in 1970. The Luries' inspiration for founding JDRF was their son, Stephen, who was diagnosed with type 1 diabetes at the age of 10.  Ever since, Carol and Erwin played a vital part in JDRF and its contributions to diabetes research, offering continual inspiration, guidance, and support working within the US and internationally. 

She was the inspiration behind three of JDRF's International Conferences on Diabetes Research, held in 1985, 1988, and 1992, co-sponsored by the World Health Organisation.  In October 1994, Carol was honoured by the Queen of Denmark and received Her Majesty's Distinguished Order of the Dannebrog for her efforts on behalf of diabetes research.  She was also appointed to New York State Council on Diabetes in 1988.  In the early '80s, both Carol and Erwin served on Advisory Boards for the National Institutes of Health - Erwin on Board of the National Eye Institute, and Carol on the National Heart, Lung, and Blood Institute's Board

Her son, James Lurie is a Board Director of JDRF in the UK as well as continuing to play an active role within JDRF in the US.  The condolences of everyone at JDRF go out to James and his family.

Michael Thornton, 12, from Canada, has proved that having type 1 diabetes doesn’t stop you living your dreams, after completing football trials with some of the biggest clubs in Europe, including A.S. Roma, Inter Milan, Manchester City and Paris St-Germain.

Michael, who lives in Toronto, Ontario, was diagnosed with type 1 diabetes aged six. It was a huge shock as there wasn’t any history of type 1 in the family, but Michael soon began to gain confidence in managing his type 1. He has since proved himself to be a top athlete, completing football trials with some of the biggest clubs in Europe.

Kicking off in Italy

Michael’s international football trials started in 2012, when two Italian scouts were so impressed by a video of Michael's soccer highlights that they invited him to Italy to spend two weeks on trial at AS Roma. While there Michael was fortunate enough to meet the captain of the team, Francesco Totti. In January 2013 Michael returned to Italy to participate in more trials with two other Italian Serie A clubs – Inter Milan and U.C. Sampdoria. Michael captured the attention of the media, being one of the first diabetics they ever had participating in their academy. After receiving a successful report by the coaches and club, he was asked to come back again.

A match with Manchester City

Michael also came to the UK in January 2013 to trial for Manchester City, where he met Roberto Mancini, Head Coach, and players from the first team and former player Mario Balotelli (pictured). Michael was able to talk about living with type 1 diabetes and about JDRF, the work we do and how he is a type 1 ambassador for the charity. He then flew to Paris, France to meet with coaches at Paris St-Germain (PSG) where this would be his last trial before returning to Canada. 

Michael and his parents have experienced a variety of world class soccer clubs and are now left with a decision to where the best environment would be for Michael to grow and develop in football.

Raising awareness of type 1 and JDRF

In August of 2012, Michael was the captain of the Canadian diabetic team, participating in the Medtronic Junior World Cup Soccer Tournament in Switzerland. Michael was lucky enough to meet the Canadian Prime Minister, in Ottawa, in November of 2012 where he raised awareness of JDRF.

He has been heavily involved with public affairs activity in Canada and has shared his type 1 stories with a number of MPs. While he travels the world showcasing his football abilities, Michael is commited to proving that children with type 1 diabetes can compete at the same level as those that don’t have the condition.

Michael said:

'My goal is to play professional football and every success I achieve will be not only for myself but for all individuals living with type 1 diabetes worldwide.'

Read Michael's story in full and watch a video of his trial with A.S.Roma »

Michael showcases his skills to Roberto Mancini

Congratulations to JDRF-funded scientist Dr Robert Langer who has been awarded the National Medal of Technology and Innovation from US President Barack Obama.

The National Medal of Technology and Innovation is awarded to inventors or innovators who have made a significant contribution to new technology and is the highest technology honour awarded by the United States. Among the first winners of the award were Steve Jobs and Steve Wozniak for the development of the personal computer.

Dr Langer has received the award for his groundbreaking research on new ways to deliver drugs into the body and ensure their controlled release. His previous work led to the development of the first FDA approved treatment for brain cancer in 20 years.

More recently Dr Langer has begun working on encapsulation and with funding from JDRF he is currently investigating materials that can effectively protect beta cells from the immune system in the body.

Encapsulation is a new way to protect transplanted islets in people with type 1 diabetes. The islets are encapsulated in a protective bubble that has tiny holes to let insulin out and glucose in. These holes are too small for the cells from the immune system to enter, so the islets are protected from both transplant rejection and the reaction that causes type 1 in the first place.

One of the challenges to successfully encapsulating islets is a lack of biomaterials that fit the criteria to successfully encapsulate islets.  Dr Langer and his team are testing new ways to create and evaluate thousands of biomaterials that may be a more effective method of encapsulation.

JDRF President Her Royal Highness The Duchess of Cornwall today met children living with type 1 diabetes – and Hollywood star Jeremy Irvine – at University College London Hospitals NHS Foundation Trust (UCLH).

Jeremy Irvine, who also supports the charity, played the lead role in Steven Spielberg’s blockbuster War Horse. This spring will see him appear alongside Nicole Kidman and Colin Firth in The Railway Man. Jeremy, who will portray a captured British officer in the World War Two epic, applied to join the army himself when he was 19 – but was rejected when the army learned that he has type 1 diabetes.

The event saw Her Royal Highness speak to patients including five-year-old Ben Wilkinson from Bushey, who was diagnosed with type 1 diabetes at the age of just two and Izzi Hickmott,15, from Brighton was diagnosed when she was ten years old. The Duchess of Cornwall also met patients’ families who face such daunting challenges following a diagnosis, which means a dependency upon multiple daily insulin injections or pump infusions simply to stay alive.

UCLH is one of the UK’s leading institutions for insulin pump therapy – a treatment which can drastically improve quality of life for those with type 1 diabetes. Insulin pumps remove the necessity of multiple daily injections and can offer improved blood glucose control, both of which are especially crucial for children.

At UCLH, 64 per cent of patients receive this form of therapy. This compares to a mere 3.7 per cent across the UK. This is one of the lowest rates of pump therapy in any developed nation worldwide, and places the UK behind the Czech Republic.

The Duchess of Cornwall was given a tour of the hospital by Karen Addington, Chief Executive of JDRF and UCLH’s Professor Peter Hindmarsh, who is a leading clinician in paediatric type 1 diabetes treatment.

Jeremy Irvine, who is from Cambridgeshire, was not the only actor present. Susan Hampshire, OBE, known for leading roles in the likes of Monarch of the Glen, was also in attendance as a supporter of JDRF.

Karen Addington said: “We are absolutely delighted to have The Duchess of Cornwall demonstrate her support for the work of JDRF. Type 1 diabetes is a challenging and serious autoimmune condition, often overlooked, which affects 400,000 children and adults across the UK. We are very thankful for her support, which will help more people understand what it is like to live with type 1 and become involved with the work that we do.”

Professor Peter Hindmarsh, consultant paediatric endocrinologist at UCLH, said: "Type 1 diabetes in children places a huge strain on families because of the need to get good long term control and also maintain normal family activities.  Things that we all take for granted - like going on a daytrip - take so much more planning. This is why projects such as the JDRF artificial pancreas are so important. Staff at UCLH work extremely hard to help families cope with this condition. The visit by Her Royal Highness is a great morale boost and will undoubtedly inspire us all to continue our efforts to support patients with this devastating condition."   

More photos of the day will be uploaded soon.

Sarah Johnson, Director of Policy and Communications, said: “The keys to reducing the risk of foot and leg amputations are twofold. We must support those living with the condition in achieving good blood glucose control to prevent complications developing. We must also push for early identification and treatment of these complications.”

She added: “The Government must also ensure that the right medical research is taking place and the outcomes of this research are reaching people. As the world's leading charitable funder of type 1 diabetes research, we will continue to push this crucial message.”

Speaking in Parliament this week, Health Minister Anna Soubry described evidence of rationing of blood glucose test strips as ‘bonkers’ and ‘unacceptable’.

She stated that ‘people with diabetes who use strips need to use them and often need to use many in a day. I am not happy if there is any form of rationing of those strips.’ She has pledged to take this issue to the Department of Health and to investigate this issue with Primary Care Trusts.

Her comments follow a meeting of the All Party Parliamentary Group for Diabetes, which raised the issue of a rationing of blood glucose test strips. JDRF holds joint secretariat of the group, and this meeting heard personal stories of people with type 1 who have experienced rationing of blood glucose test strips.

Anna Soubry added that the introduction of a ‘Diabetes lead’ in every Clinical Commissioning Group (CCG) provides an opportunity to improve locally delivered services. 

She concluded that “I have been alerted to problems with glucose meters and pumps… I am still concerned if there is not the availability that there should be, right across the NHS, notably for all sufferers of diabetes 1.”

Sarah Johnson, Director of Policy and Communications at JDRF said: ‘At JDRF we couldn’t agree more that rationing test strips for people with type 1 is totally ‘bonkers’, so we welcome the spotlight the Minister’s comments have put on this issue. Research has demonstrated time and again that the better control people with type 1 can achieve over their glucose levels, the lower their risk of developing the long term complications of this condition, so rationing glucose strips does not make sense on any level.’

The ‘microbiome’, the population of bacteria that lives in the gut, has been implicated in the development  of type 1 diabetes for some time.

Researchers in Australia have uncovered for the first time exactly how insulin attaches to cells in the body.

The new study published recently in the prestigious journal Nature, showed in depth how insulin binds to cells in the body. The team, led by Professor Mike Lawrence, revealed for the first time the 3D view of insulin bound to a cell. From this, they could determine exactly which part of the insulin molecule binds to the ‘receptor’ for insulin on the outside of the cell. 

While researchers have known for many years that insulin attaches to the cells and allows glucose to enter, exactly how that attachment occurs has not been known until now.

Understanding more about how insulin attaches to cells at a molecular level will help researchers develop more effective insulin products. The insulin products available at the moment do not behave exactly like the insulin produced by beta cells and lots of researchers are looking for ways to make faster and more effective insulin.

Dr Maebh Kelly, Research Communication Officer at JDRF said, ‘This is a interesting study that sheds some new light on insulin’s action in the body. Understanding exactly how insulin works to let glucose into cells will help researchers develop insulin that can get glucose into the cells faster than the insulin currently on the market.’

They say a ‘man’s best friend is his dog’ and for JDRF Youth Ambassador Amy Wilton, 17, from Fareham, this is only too true as her best friend is her doting whippet, Holly (aged 10).

Amy has been living with type 1 since the age of five and the relationship between her and Holly goes deeper than just owner and pet. Whenever her blood glucose levels start to drop Holly picks up on this. The dog will lick her hand, jump up at her and stare at her until she realises something must be wrong and this dedicated dog doesn’t stop, she is on the look-out 24 hrs a day!

Due to the loyalty that her dog Holly shows, Amy wanted to give something back and entered a picture of Holly taken on Hill Head beach into the RSPCA’s Young Photographer Awards 2012.

Amy came first in the award and was presented with a trophy and a camera by the RSPCA’s vice president Bill Oddie at an award ceremony.

A huge congratulations to Amy and Holly – well done from everyone at JDRF!

For full details on this story please go to: http://www.portsmouth.co.uk/news/star-pet-helps-amy-win-award-1-4633901

JDRF’s own Tom Brobson has recently taken part in an artificial pancreas clinical trial, and made a video about his experience.

Tom is the National Director for Research Investment Opportunities at JDRF in the US. He has been involved in a number of artificial pancreas trials over a number of years, so he was understandably delighted to have the opportunity to take part in trial that takes the system out of the hospital into the real world.

Tom wore the artificial pancreas for three days and nights as part of a clinical trial run by a group of researchers at the University of Virginia. While wearing the artificial pancreas systems, he was still involved in the major decisions about his insulin dosing, but the system took charge of 'fine tuning' his control.  

The video is an excellent example of how JDRF has helped this research progress from a concept to a working system that is now in clinical trials outside of a hospital setting. But there is still a way to go before the clinical trials are completed.

The artificial pancreas consists of an insulin pump, a continuous glucose monitor and a computer software programme which can take the readings from the glucose monitor and tell the pump when to administer insulin. In this way, blood glucose levels can be tightly controlled with very little input from the user.

Similar trials are currently being conducted in the UK by Dr Roman Hovorka at the University of Cambridge. JDRF is providing funds so that Dr Hovorka can test the ability of the artificial pancreas system his team have developed to control blood glucose levels overnight in children.

US President Barack Obama has signed a bill to renew the Special Diabetes Program, with a $150 million yearly investment approved by the US Congress.  

The Special Diabetes Program (SDP) has been funded by the US since 1998 and is a program which exists to advance type 1 diabetes research at the National Institutes of Health (NIH), while also funding treatment, education and prevention for type 2 diabetes.  Since its inception the SDP has demonstrated tangible results in type 1 diabetes research and has enabled scientists to make significant advances in cure therapies, prevention studies and treatment improvements. These have included the artificial pancreas project and groundbreaking advances in vision and improvement among people with diabetic eye disease.

Draft guidance published today shows that ranibizumab (Lucentis) should now become available on the NHS for some people with Diabetic Macular Oedema.

NICE initially rejected Lucentis as a treatment for diabetic eye disease on cost effectiveness grounds in guidance published in November 2011. Since then, the drug’s manufacturer, Novartis, has agreed a Patient Access Scheme reducing the cost of the treatment to the NHS. Novartis also submitted further information showing the treatment’s effectiveness in a particular group of patients.

NICE’s decision follows hot on the heels of a similar decision taken by NHS Scotland in December.

Rachel Connor, Head of Research Communication at JDRF, says:

‘This is good news for people with diabetes in England and Wales. JDRF was involved in the early phases of developing ranibizumab, which provides a new option for treating diabetic retinopathy, and so it’s great that this investment will now be able to benefit people living with type 1 diabetes in the UK.’ 

Media reports today show the UK has the world’s fifth-highest rate of children with type 1 diabetes. These figures come from an International Diabetes Federation report published in 2011.

The UK's rate is about twice as high as that in Spain (13) and France (12.2), 50% higher than Ireland's (16.3) and a third more than the Netherlands (18.6), Germany and New Zealand (both 18). The league table covers 88 countries where the rate of incidence of type 1 diabetes is available, as many do not record the incidence of the condition.

The most common age for developing type 1 diabetes is between 10 and 14 but in recent years the greatest increase in incidence is in the under-fives group, in which it has been rising at a rate of five per cent each year.

Whilst scientists have made huge leaps in understanding type 1 diabetes in the last decade, the exact cause is still being researched. The condition results from an autoimmune response, where the body’s own defences (the immune system) turn against the cells of the pancreas that produce insulin, a response probably caused by a mix of genetics and environmental factors. There is nothing that children with type 1, or their parents, could have done to prevent them developing the condition.

Sarah Johnson, Director of Policy and Communications at JDRF, the type 1 diabetes charity, commented: "We join Diabetes UK in calling for greater awareness of the symptoms and first class healthcare once children are diagnosed, but add that the UK Government's investment in medical research to understand the causes of, and to help cure, type 1 diabetes is also woefully inadequate to face the challenge of type 1 diabetes, and its impact on our children, now and in the future."

In the past 40 years we have funded £1 billion of the best research to cure, treat and prevent type 1 diabetes. Find out more about our research and how you can join us in finding the cure

Local boy and JDRF T1 Youth Ambassador Nick Taylor, 16, from Claygate joined JDRF staff at Canary Wharf on the 18 December to take part in the last leg of the British Inspiration Trust BRIT 2012 Challenge.

JDRF staff and supporters walked with Phil Packer MBE, founder of BRIT, in the last mile of his incredible 2,012 mile journey, the equivalent of approximately 310 marathons in 331 days, and show their support for such a great cause. 

JDRF’s CEO, Karen Addington, who is a BRIT advisor, was invited to join Phil Packer on the last mile and was joined by supporters Nick and mum Sally. Nick, a Reed’s School student was diagnosed with type 1 diabetes aged three, was proud to represent the 29,000 children who live with the life-long condition in the UK.

Nick said: “It was a great day and I was really pleased that I was able to take part in such a momentous journey and join the JDRF team. JDRF has played a big part in my family’s lives since I was diagnosed and we try and do as much as we can to raise awareness and vital funds to support research, so that JDRF can one day find the cure.

Phil is a true hero and someone to look up to, as he hasn’t let anything hold him back. I guess you could use Phil’s inspiration and courage when it comes to type 1 and controlling  your condition, instead of it controlling you and don’t let it stop you doing anything.”

JDRF’s CEO, Karen Addington said: “Phil is an inspiration to each and every one of us and we are deeply moved by the work that Phil does. This challenge particularly showed his courage and strength and is living proof that anything is possible. We were delighted to support him on his last part of his journey and wish Phil and his team all the best with the new centre. A huge congratulations to Phil for completing an amazing challenge – well done!”

Talking about his experiences Phil Packer said: “This has been an extraordinary year and completing this challenge is a landmark way to finish. 2013 needs to be the year that BRIT comes to life and I need businesses to step up and help us do that. The challenge now is about building a legacy for a part of our society; young people post-traumatic experiences desperately in need of our help. I’m grateful to have both Karen’s and JDRF’s support along with other charities – so thank you.”

The journey which started on the 24 January saw Phil walk the length and breadth of the country to raise awareness for BRIT and aims to raise £15 million to build the first BRIT Centre of Inspiration in West Sussex for young people facing adversity.

Much of this time was spent walking with young people both able bodied, like Nick, and with disabilities from across the mobility and cognitive spectrum that have inspired Phil to push forward with his aspiration to build a centre that caters for young people of every background and disability.

It has been a huge personal achievement for Phil who suffered a severe spinal cord injury, whilst on operational duty in Her Majesty’s Forces, where he served for 17 years. Phil was told that he was unlikely to walk again, so for him walking just a mile is the equivalent of three or four miles for someone without a spinal cord injury.

For further information on Phil or the BRIT Challenge please visit, Phil Packer's website or the British Inspiration Trust's website .

View photos from the day below: 

JDRF was delighted to be chosen as the beneficiary charity of the live and silent auctions at the annual Christmas lunch of the Association of Women Travel Executives (AWTE).

The lunch was held last Tuesday at the Royal Garden Hotel in Kensington and was a glamorous affair where the champagne flowed and entertainment was plentiful.

Amanda Taylor chose to support JDRF when she became chair of the ATWE board. Amanda's nephew Freddie has type 1 diabetes, so the search for the cure is a cause close to her heart. When she was asked to nominate a charity to benefit from the Christmas lunch, Amanda did not hesitate in choosing JDRF.

Pilot and JDRF supporter Douglas Cairns, who has type 1 himself, was the after dinner speaker and wowed the audience with his tales of adventure, from flying to the North Pole to his around the world flight, all to raise awareness of type 1.

The auction prizes included holidays, hotel stays and a flight with Douglas himself and raised nearly £10,000 for JDRF.

Louise Ingham, Development Manager for the South, East and London, said:

‘We are hugely grateful to Amanda and the AWTE for choosing to support JDRF and to everyone who bid in the auction. The money raised at the event will help us get one step closer to finding a cure for type 1 diabetes’.

Image L-R: Douglas Cairns, Amanda Taylor, Louise Ingham

Matthew Wood, 39 from Wallington, has completed a full month wearing a blue Morphsuit to raise awareness for JDRF. The Sutton Guardian has featured Matthew's story on the front page of today's newspaper, and also produced a short video about his challenge which you can view on their website

World Diabetes Day challenge

Matthew’s challenge started on World Diabetes Day – 14 November 2012 – and he has since attended client and Board of School Governors meetings, ran his Scout and Brownie groups, done charity circuit training sessions, seen Gary Barlow in concert at the Royal Albert Hall and even met Santa Claus as Morph.

Matthew came up with this unusual fundraising challenge after his step-sister Caryn Bishop, a nurse from West Molesey, son Joseph was diagnosed with type 1 diabetes in August 2009, aged eight.

Joseph, a pupil at Twickenham Prep School, Hampton, become lethargic, was urinating excessively and had a constant thirst, even getting up in the middle of the night to drink from the bathroom tap. Caryn knew the symptoms of type 1 so visited her GP and they were sent straight to hospital, where this was confirmed.

Caryn said:

'After his first insulin injection, I remember Joseph asking me if he was better and I had to explain he would need these injections and finger prick tests for the rest of his life – it was heartbreaking explaining this to my eight year old son. Having to inject Joseph was not something I prepared myself for, nor was it in any parenting book, nor in my training as a nurse. I cried hysterically after he looked at me and said ‘its ok mum, it didn’t hurt’. Now some 9,000 finger prick tests and over 2,000 injections later Joseph receives insulin via a pump and does everything any other 11 year old does. He has learnt to control his type 1 instead of it controlling him.'

Matthew said:

'This was just one month out of my life and I wanted to do a challenge that was different. You will be pleased to know that I had two suits which I alternated every day and wore for approximately 16 hours per day. Joseph, unfortunately, doesn’t have a break from type 1 and by doing this I hoped to educate people about type 1 and the good work JDRF does in funding research to find the cure.'

JDRF would like to thank Matthew for coming up with such an unusual and brave fundraising challenge. If you would like to take on your own fundraising challenge, have a look at 'Your fundraising stories' and get inspired!

The Royal College of Paediatrics and Child Health has today announced that a quarter of children and around half the population have low vitamin D levels. News stories have linked this to a rise in health conditions including diabetes. 

The organisation is urging that supplements should be made easily available.

The main role of vitamin D in the body is to keep bones and teeth healthy and there are many benefits to ensuring that you get the recommended daily allowance. The main source of vitamin D is sunlight but it is also found in oily fish, eggs and fortified cereals. 

Although low levels of vitamin D have been associated with increased risk of developing type 1 diabetes, this link has not been conclusively proven.  Importantly, no clinical trials have as yet demonstrated that adding more vitamin D to a diet can prevent type 1.

The Department of Health currently recommends:

• All pregnant and breastfeeding women should take a daily supplement containing 10 micrograms of vitamin D, to ensure the mother’s requirements for vitamin D are met and to build adequate fetal stores for early infancy.
• All babies and young children aged 6 months to 5 years should take a daily supplement containing vitamin D in the form of vitamin drops, to help them to meet the requirement set for this age group of 7.0-8.5 micrograms of vitamin D a day. 
• However, babies who are fed infant formula will not need vitamin drops until they are receiving less than 500ml (about a pint) of infant formula a day, as these products are fortified with vitamin D. 
• Breastfed infants may need to receive drops containing vitamin D from one month of age if their mother has not taken vitamin D supplements throughout pregnancy.
•  People aged 65 years and over and people who are not exposed to much sun should also take a daily supplement containing 10 micrograms of vitamin D

When Jayson and Vicky Shaw from Bedford heard that their son Joshua’s clinic may not be able to hold their annual Christmas party due to lack of funds, they both sprang into action. It wasn’t long before the party was back on as they quickly gathered support from the local community and the Rotary Club of Bedford. They even had an amazing offer of free entertainment from Mad Science.

The party was held on Wednesday 12 December and twenty three children (who were all affected by type 1 diabetes in some way) enjoyed an afternoon of interactive science fun by Nitro Nick and temporary festive tattoos from Vicky. They also tucked into a cooked meal and even had a special visit from Santa, who treated the children to a gift and a bag of magic reindeer food to sprinkle on their garden on Christmas Eve.

Vicky and Jayson would like to thank everyone who helped to make the Christmas party a success. They would also like to give a special thank you to Mad Science for providing entertainment for the children free of charge.

Today the Scottish Medicines Consortium approved Lucentis® (ranibizumab), the first medicine licensed to treat visual impairment due to Diabetic Macular Oedema, for restricted use within NHS Scotland.

This decision puts Scotland ahead of the rest of the UK in granting access to Lucentis. The makers of the drug, Novartis, estimate that the decision means that approximately 4000 people living with Diabetic Macular Oedema in Scotland will now be eligible to benefit from the treatment.

Novartis has worked with the Scottish Medicines Consortium to put in place a Patient Access scheme that helps to ensure the new treatment meets cost effectiveness criteria set by NHS Scotland.

Rachel Connor, Head of Research Communication at JDRF comments:

‘JDRF is delighted that the Patient Access Scheme for Lucentis means that people living with Diabetic Macular Oedema in Scotland may now be eligible to access to this innovative treatment. Lucentis is a new tool, which JDRF helped to develop, for clinicians working with people with diabetes.  It has the potential to not only prevent further vision loss, but also repair some of the damage that has already occurred.’

Phil Packer MBE, the founder of the British Inspiration Trust (BRIT) is on the last leg of his incredible 2,012 mile journey, that will finish on the 18 December 2012 and would have seen him walk the equivalent of approximately 310 marathons in 331 days. JDRF is delighted to be able to join Phil in walking the last mile of his journey and will be there to show our support for such a great cause.

22,000 'additional' people in England and Wales died last year because of diabetes and its complications, shows the National Diabetes Audit, released today. The report noted 'The years of life lost are especially notable in people with type 1 diabetes'.

The report highlighted the significantly increased risk of heart disease for people with diabetes, who are 48% more likely to have a heart attack than people without the condition. It also showed that people with diabetes were more than 25% more likely to have a stroke and twice as likely to need dialysis or need a kidney transplant.

The risk of complications from diabetes can be reduced by achieving good long term blood glucose control, however 70% of people with type 1 diabetes, including 85% of children, are not managing to keep their long term blood glucose measurement within the target range.  There is also a 'post code lottery' of access to the technologies and treatments, like insulin pumps and continuous glucose monitors, to help manage the condition.

Karen Addington, Chief Executive of JDRF, said:

'These are worrying figures for anyone with type 1 diabetes, or who has a child or loved one living with the condition and they highlight, once again, why increased investment in research to cure, treat and prevent type 1 diabetes and its complications, and access to the treatments that come from this research is so vital.'

Find out about JDRF's work to cure, treat and prevent type 1 diabetes, and how you can get involved with research and campaigning for increased government focus on the condition.

Scientists at the University of Cambridge are one step closer to developing insulin producing beta cells from human stem cells.

In the study, published in the journal Diabetologia this month, the researchers have identified the signals needed to turn stem cells in pancreatic progenitor cells which are the type of cell that eventually becomes a beta cell.

They found that a molecule called Actin, stops stem cells being turned into pancreatic cells and helps them become liver cells. By blocking Actin, the team could increase the number of stem cells becoming pancreatic cells.

Human stem cells can multiply in the lab and have the potential to be turned in to a plentiful supply of beta cells that could be transplanted into people with type 1, to replace the insulin producing cells that have been destroyed. Although some researchers have successfully turned mouse stem cells into beta cells, it is proving more difficult for human stem cells.

One of the major roadblocks to stem cell therapies is that methods to turn them into more specialised cells are not very reproducible and can produce variable results. By understanding more about the specific signals need to turn stem cells into beta cells, scientists can develop more robust and reproducible methods to make beta cells in the lab.

Maebh Kelly, Research Communication Officer at JDRF commented, ‘This study gives us more insight into the specific molecular processes that underpin the change from stem cells into pancreatic progenitor cells.  Studies like this are important as we will need to understand much more about how stem cells develop before they can be used in clinical studies.’

JDRF supporter Jeremy Irvine, star of blockbuster War Horse and new release Great Expectations, was on Sunrise, Sky News this morning (Thursday 29 November 2012). He talked about his work with JDRF, artificial pancreas research and life with type 1 diabetes to presenter Stephen Dixon, who also has type 1.

Jeremy has previously been involved with JDRF funded research into the artificial pancreas. Find out more about this project here.

Neil McDonald is a firm candidate for JDRF’s ultimate fundraiser, after raising £120,000 through his Climbing for a Cure campaign. Neil has taken part in a series of exhibitions for JDRF, and scaled Mount Everest, the world’s highest peak at 8,848 metres, this May.

The Aberdeen-based dad started to raise funds for JDRF after his 10-year-old daughter, Darcey (pictured with Neil), was diagnosed with type 1 at the age of three. His wife Linzie has also tirelessly fundraised for the cure, organising the Climbing for a Cure Bond Ball in September 2011, which raised an amazing £80,000 for JDRF.

In preparation for the Everest climb, Neil and his climbing partner, Radek Dusatko, scaled some of the world’s highest mountains. To qualify for the Everest climb they had to climb Aconcagua (the highest mountain in South America), which is 7,000 metres and took nearly three weeks. To qualify for this the pair had climbed Mont Blanc, and at the start of the campaign Neil climbed Ben Nevis to train. The whole process took two and a half years, with Neil training five days a week, every week.  

Neil was on Everest itself for two months, in between Everest Base Camp and the higher camps. As well as the extreme physical challenges of altitude sickness and hydration, the expedition was mentally taxing. Neil helped rescue one stranded climber, for which he was nominated for the title of Sunday Mail Great Scot of 2012.

Neil said:

‘The thought of Darcey sustained me. The pain was nothing compared to the difficulties my little girl has had to go through with type 1, living with injections of insulin and pinprick blood testing daily just to keep her alive. I knew that I could simply turn around and go back down but Darcey doesn’t have that choice. She has to deal with her situation every day forever until we get a cure.’

The training and exhibition were completely funded by Neil, which meant that all the money received through sponsorship and donations will go directly to supporting JDRF’s work.

Neil’s sponsor, Fifth Business, have put together a video about Neil’s Climbing for a Cure campaign.

There have been reports in the media this morning about islet cells as a cure for type 1.

An islet transplant involves preparing islets from a deceased donor's pancreas, so that they can be given to someone with type 1. The islets are then injected into the large blood vessel that feeds the liver of the person with type 1. To be able to give someone with type 1 the number of islets needed to control their blood glucose levels often requires two separate infusions. Following a transplant majority of patients only require tiny amounts of regular insulin and some do not require insulin at all.

JDRF funding enabled a team based in Edmonton, Canada, to define the conditions for a successful islet transplant in the 1990’s. Since the first islet transplant in 1999, more than 800 islet transplants have happened worldwide. The NHS was the first healthcare organisation in the world to adopt islet transplants as a proven treatment (specifically for people with hypoglycaemia unawareness), so the success of transplant centres around the country is a great testament to the progress that has been made from the early days of JDRF’s funding in this field.

Islet transplants are not a common treatment for people with type 1 at the moment and are usually reserved for people who have severe hypoglycaemia unawareness. This is partially because transplants are inefficient - many of the cells die in the period directly after transplant. In addition, after an islet transplant, people need to take strong drugs that suppress the immune system, leaving the body vulnerable to infections.

Because islet transplants do not tackle the underlying autoimmune cause of type 1, the immune system can eventually attack the new islets so about five years after transplant, many people find that they need to increase their insulin dose again.

JDRF is funding lots of research to make islet transplants more efficient and to find alternative sources of beta cells that could be transplanted to people with type 1. You can read more about our beta cell therapies programme here.

Local man Matthew Wood, 39, has pledged to wear a blue Morph suit every day for a month to help raise awareness and funds for JDRF. 

Matthew’s challenge started on World Diabetes Day – 14 November 2012 – and he has continued with his day to day life as Morph attending client and Board of School Governors meetings, running his Scout and Brownie groups, doing charity circuit training sessions, seeing Gary Barlow in concert at the Royal Albert Hall tonight (27 November) and even meeting Santa Claus as Morph.

The man behind the Morph came up with this unusual fundraising challenge after his step-sister Caryn Bishop, a nurse from West Molesey, son Joseph was diagnosed with type 1 diabetes in August 2009, aged eight.

Joseph, a pupil at Twickenham Prep School, Hampton, become lethargic, was urinating excessively and had a constant thirst, even getting up in the middle of the night to drink from the bathroom tap. Caryn knew the symptoms of type 1 so visited her GP and they were sent straight to hospital, where this was confirmed.

Caryn said:

'After his first insulin injection, I remember Joseph asking me if he was better and I had to explain he would need these injections and finger prick tests for the rest of his life – it was heartbreaking explaining this to my eight year old son. Having to inject Joseph was not something I prepared myself for, nor was it in any parenting book, nor in my training as a nurse. I cried hysterically after he looked at me and said ‘its ok mum, it didn’t hurt’. Now some 9,000 finger prick tests and over 2,000 injections later Joseph receives insulin via a pump and does everything any other 11 year old does. He has learnt to control his type 1 instead of it controlling him.'

Joseph is just one of 29,000 children to live with type 1 diabetes in the UK, with 400,000 people living with the condition.

Matthew said:

'This was just one month out of my life and I wanted to do a challenge that was different. You will be pleased to know I have two suits which I alternate every day and approximately wear for 16 hours per day. Joseph, unfortunately, doesn’t have a break from type 1 and by doing this I hope to educate people about type 1 and the good work JDRF does in funding research to find the cure.'

To follow Matthew’s ‘Month as a Morph’ challenge, visit his Facebook page for daily updates http://www.facebook.com/matthew.wood.9484 and if you would like to donate please do so here: http://www.justgiving.com/MattsmonthasaMorph-Wood

On 28 November 2012, Leicester Grammar School will be holding an assembly to raise awareness of type 1 diabetes and funds for JDRF. 

The initiative is fully supported by the pupils who live with type 1 including Year 12 student Robin McFarland, aged 16, from Leicester. Robin has been living with type 1 for the past four years and in order to control the autoimmune condition receives a continuous supply of insulin through an insulin pump which helps him to manage his type 1 diabetes. 

Helena Cooper, aged 18 from Kibworth, also supports the latest project. Helena was diagnosed with type 1 at age six and is in Year 13 at the school.

There are 400,000 people living with type 1 diabetes in the UK, 29,000 of these are children with the common aged of diagnosis being between 10-14 years old.

Both pupils and teachers are supporting the campaign and Head of Year 11 Mr Thacker knows only too well the importance of raising awareness within the school, having been diagnosed with type 1 diabetes himself.

Mr. Thacker said:

'Both on a professional and personal level I felt it was essential to educate the school, so everyone is aware of the condition and how to look for signs and symptoms. It’s vital that the pupils at the school who have type 1 are not treated any differently and get the same education as everyone else. We really hope that it helps to raise awareness of JDRF, who do a fantastic job in trying to find the cure.'

Following on from the success of the "Talking T1" pack for primary schools, and with support from Lilly, a leading healthcare company with a long heritage in diabetes, JDRF has created “Talking T1” – Teens with type 1 diabetes, an education resource to help schools support secondary school students with type 1 diabetes and their families across the UK. 

Lee Newman, JDRF’s Development Manager for Midlands said:

'We aim to educate the educators to raise awareness and understanding of type 1 diabetes and provide school staff with a practical tool to support the needs of young people with type 1 in schools. Unfortunately, more and more children are being diagnosed each year, so it is vital that people are aware of the condition. Children spend nearly as much time at school as they do at home, so helping schools prepare so that the condition can be effectively managed in the classroom is really important. I ask every school to order its free pack and begin “Talking T1”. We are grateful to Leicester Grammar School for helping to raise awareness and wish them every success on the day.'

To help raise funds on the day, Librarian Trish Ingham along with her knitting group, The Knatty Knitters, will be knitting the ’12 knits of Christmas’ which will be raffled as part of the fundraising initiative.

A new research study has evaluated how the DAFNE (Dose- Adjustment for Normal Eating) programme impacts quality of life and HbA1c levels of people with type 1.

In this study, researchers measured participants’ HbA1c eight weeks before the DAFNE course and at six and 12 months after. They found that there was an improvement in HbA1c levels six months after the course and the level of improvement was greater in people who had a higher HbA1c in the first place. Some of the improvement in HbA1c levels was lost by 12 months, but even so levels remained better than before the course.

The researchers also looked at how DAFNE impacted the quality of life of people with type 1. A significant number of the study participants reported an improvement in their quality of life at six and 12 months after the course.

DAFNE is a structured education programme for people with type 1 that focuses on adjusting insulin doses based on the amount of carbohydrate in a meal. No foods are forbidden on the DAFNE programme. The course runs over five days with a booster session six weeks later and is delivered to groups of no more than eight at a time.

Maebh Kelly, Research Communication Officer at JDRF commented, ‘This new study confirms what many people with type 1 tell us about the value of structured education in helping them manage their condition. The importance of programmes like DAFNE in improving quality of life as well glucose should not be underestimated.’

Janey Rossiter, of Modbury in Devon, ran the Plymouth 10k along with her family and friends on 4 November to raise money and awareness for JDRF.

Janey’s husband Richie, 42, was due to run the Plymouth Half Marathon in May but passed away very suddenly, so in his memory friends, family and Richie’s workmates took part in the Plymouth 10k as a fitting way to remember him. ‘Richie’s Racers’ raised £5,600 and rising for JDRF, as one of Janey and Richie’s daughters, Dani (age 4), has type 1 diabetes.

Janey commented:

'There was such a great atmosphere and team-vibe amongst us, all supporting and cheering each other on, especially us slower runners! That is exactly what Rich would have wanted us to do. It means a lot to me and Richie's family to think that he was that well thought of and loved that nearly 70 people would step up and put themselves forward for this challenge.  Everyone was so determined to get round and to do it for Rich. I didn't make it around without shedding a few tears along the way - when the real reason of why I was running started to sink in. I don't think any of us could have imagined the fantastic response and generosity we received from both runners and supporters alike. Currently £5,600 and still rising! Out of this world!'

To donate, please visit: http://www.justgiving.com/richies-racers

JDRF-funded researchers at Northwestern University Chicago have developed a new way to alter the immune system to stop autoimmune responses like that in type 1 diabetes. The team used nanoparticles to selectively stop the part of the immune system that causes an unwanted response.

The nanoparticles were attached to an ‘antigen’ for multiple sclerosis. Only the immune cells involved in the response that causes multiple sclerosis recognise this antigen so they are selectively targeted. The nanoparticles then reset these immune cells so that they no longer cause an unwanted immune response. In this way only the cells that cause the attack are affected leaving the rest of the immune system intact.

Multiple sclerosis is an autoimmune condition in which the immune system attacks a protein called myelin on the nerve cells. The researchers found that after injection with the nanoparticles, the immune system stopped recognising myelin as foreign and no longer attacked the cells that contain myelin. The nanoparticles are made from the same material as biodegradable stitches and are 20 times thinner than human hair.

So far the researchers have only used nanoparticles to try and treat multiple sclerosis but they believe that the nanoparticle technology can be applied to any autoimmune condition. By replacing the multiple sclerosis antigen with an antigen that is selectively recognised by the immune cells that cause type 1 diabetes, this technology could be applied to people with type 1.

Maebh Kelly, Research Communication Officer at JDRF said, ‘This is exciting new technology that may have great implications for immune therapies for type 1. By applying this technology with an antigen that is specific to type 1 diabetes it could reset the immune system so that it does not recognise insulin producing cells as foreign.’

New evidence has been published about diabetes and vitamin D from researchers at the University of California, San Diego School of Medicine, who studied development of insulin dependent diabetes in soldiers.

Because the US Department of Defence stores blood samples from all soldiers at recruitment, the team of researchers was able to retrospectively measure the levels of vitamin D3 in blood samples from people who had gone on to develop insulin dependent diabetes in the six years since the samples were taken.

They compared these vitamin D levels to the levels in samples taken from people who didn’t develop the condition. They found that people who went on to develop insulin dependent diabetes were more likely to have had low levels of vitamin D in their blood sample.

The study compared 1000 soldiers with insulin dependent diabetes (type 1 and type 2 were not differentiated) with 1000 soldiers who had not developed the condition.

Although low levels of vitamin D have been associated with increased risk of developing type 1 diabetes, this link has not been conclusively proven.  Importantly, no clinical trials have as yet demonstrated that adding more vitamin D to a diet can prevent type 1.

The main role of vitamin D in the body is to keep bones and teeth healthy and there are many benefits to ensuring that you get the recommended daily allowance. The main source of vitamin D is sunlight but it is also found in oily fish, eggs and fortified cereals. 

However, taking more vitamin D than is recommended has not been proven to have any extra health benefits and there are some side effects associated with prolonged overdoses.  The Department of Health says that taking 25 micrograms (0.025mg) or less a day of vitamin D supplements is unlikely to cause any harm

The Department of Health currently recommends:

• All pregnant and breastfeeding women should take a daily supplement containing 10 micrograms of vitamin D, to ensure the mother’s requirements for vitamin D are met and to build adequate fetal stores for early infancy.

• All babies and young children aged 6 months to 5 years should take a daily supplement containing vitamin D in the form of vitamin drops, to help them to meet the requirement set for this age group of 7.0-8.5 micrograms of vitamin D a day. 

• However, babies who are fed infant formula will not need vitamin drops until they are receiving less than 500ml (about a pint) of infant formula a day, as these products are fortified with vitamin D. 

• Breastfed infants may need to receive drops containing vitamin D from one month of age if their mother has not taken vitamin D supplements throughout pregnancy.

•  People aged 65 years and over and people who are not exposed to much sun should also take a daily supplement containing 10 micrograms of vitamin D

The DAFNE User Action Group (DUAG) has submitted an e-petition to the Government to ask them to establish a nationally funded structured education programme for people with type 1.

The availability of structured education for people with type 1 varies across the country with many people never undergoing any form structured education. Programmes like DAFNE have been shown to improve the quality of life of people with type 1 by giving them the confidence to take more control of the condition.

DAFNE (Dose Adjustment for Normal Eating) is a structured education programme that provides people with type 1 with the skills to estimate the amount of carbohydrate in a meal and inject the correct dose of insulin.

 Follow this link to sign the petition http://epetitions.direct.gov.uk/petitions/41345 

If the DUAG e-petition gets at least 100,000 signatures, it will be considered for debate in the House of Commons. You can find more information about how the House of Commons deals with e-petitions on the Backbench Business Committee website

Clarence House goes 'Royal Blue' for World Diabetes Day

This year Clarence House turned blue for the first time to mark World Diabetes Day and Her Royal Highness The Duchess of Cornwall's Presidency of JDRF. 

Clarence House joined landmarks across the UK and the rest of the world in marking the day.

The Duchess of Cornwall, who is currently on a tour of Papua New Guinea, Australia and New Zealand to mark The Diamond Jubilee, has agreed to Clarence House “going blue” to show support for the 400,000 people living with type 1 diabetes in the UK, of which 29,000 are children.

Karen Addington, Chief Executive, JDRF said:

'We are thrilled to have The Duchess of Cornwall as JDRF’s President. We are working hard to support research to cure, treat and prevent type 1 diabetes and we are very grateful to Her Royal Highness for her efforts to raise awareness of this serious autoimmune condition.'

World Diabetes Day messages

JDRF T1 Youth Ambassadors, children and young people from across the UK, have sent their own messages of thanks and hope for the cure for type 1 diabetes to HRH. These were delivered in a World Diabetes Day card to Clarence House by a special envoy of T1 Youth Ambassadors and JDRF’s mascot Rufus, the Bear with Diabetes.

Delivering the card to Clarence House were Amy Wilton (17), Eleanor Lotsu (12), Sam Barkway (11) and Bella Radley (6).

Amy was diagnosed with type 1 diabetes aged five years old, and since then has had over 17,000 insulin injections to help her manage her condition. Since diagnosis she has been a passionate supporter of JDRF, even sharing her story with President Obama at the charity’s US lobbying event Children’s Congress in 2008. 

Bella, Eleanor and Sam all control their condition with an insulin pump that delivers a continuous supply of insulin. Bella was two years old when she was diagnosed, and Eleanor and Sam were both seven. 

Sam told us:

‘I am thrilled to be able to represent the 29,000 children who have type 1 diabetes just like me. It’s really exciting to get to visit Clarence House and I will never forget it.’

Cambridge Wellcome Trust clinical research facility

Amy has previously spoken to Her Royal Highness about living with type 1 diabetes when she visited the Cambridge Wellcome Trust clinical research facility in April 2012 to learn more about JDRF and type 1 diabetes research. 

Also present at the visit were BBC Radio 4’s Today Programme presenter Justin Webb, his wife Sarah Gordon and their son Sam, who was diagnosed with type 1 diabetes in 2008.

Justin Webb commented:

'I am hugely grateful to The Duchess for taking an interest in JDRF and in an area of medical charity work that is outside the mainstream - but that promises a new lease of life to the children whose lives have been turned upside down.'

Amelia Lily has shown her support for JDRF and World Diabetes Day.

She told us:

‘I was excited to hear that for World Diabetes Day, Clarence House will be turning blue to mark Her Royal Highness The Duchess of Cornwall's presidency of JDRF, the type 1 diabetes charity. It’s a great charity that does some fantastic research in order to find the cure for people living with type 1, just like me.’

The pop star found fame in the eighth series of the X Factor in 2011, mentored by Kelly Rowland. Amelia’s debut single ‘You Bring Me Joy’ was released in September this year and charted at number two in the UK singles chart.

She has been tireless in her efforts to raise awareness of type 1 diabetes and to educate the general public and challenge some of the myths and misconceptions. In doing so she has become a role model for children and young people living with the condition.

Scientists have developed a new type of nasal spray to deliver insulin through the nose.

The team from the University of Sunderland have developed a way to deliver basal insulin through the nose so that it is gradually released into the body during the day. The researchers, led by Dr Hamde Nazaar, have stabilised the nasal insulin spray so it remains in the nose and is not cleared out by the body.

After the insulin is administered as a spray, it begins to get warmer due to the heat of the body. As it gets warmer, it turns into a gel. Once the insulin is in this gel form it becomes more stable, and is released into the body gradually.

So far, the team have tested their new insulin formula in diabetic rats. The insulin spray was able to keep blood glucose levels low for up to twelve hours, but bolus injections are still needed at mealtimes.

Currently the most common way to administer insulin is by multiple daily injections, with a combination of long-acting 'basal' insulins and short-acting 'boluses'. Insulin cannot be taken in a tablet form as it gets broken down by the digestive system and so by the time it enters the blood it is inactive. A nasal insulin spray would avoid this issue, as the insulin would enter the body through the lungs and not the stomach.

Maebh Kelly, Research Communication Officer at JDRF said, ‘A nasal insulin spray would reduce the burden of injections that people with type 1 have to face every day. This study shows proof-of-principle that nasal spray could be a viable replacement for basal insulin injections, but it remains to be seen how well this spray will work in people with type 1.’

Millie Hainge, a 10 year old pupil at Milverton House School in Nuneaton, is asking teachers and pupils within the school to wear an elastic band around their wrists on the 14 November, World Diabetes Day which they have to ‘ping’ each time they eat or drink any food stuffs containing carbohydrates.

Millie (pictured) is one of 29,000 children in the UK living with the life-long condition and is keen to raise awareness of type 1 and JDRF. JDRF is determined to find the cure, so children like Millie wouldn’t have to constantly do finger prick tests and carb count to help keep their type 1 under control.

Millie, who was diagnosed with type 1 diabetes in November 2011, said:

'The idea of ‘pinging’ an elastic band every time you eat or drink foods containing carbohydrates is similar to someone with diabetes continually finger pricking to check blood glucose or injecting insulin. We all take for granted that we can eat and drink anything at any time, so this is a fun way of helping my friends and teachers understand what I have to do every day to stay healthy.'

Mr Pipe, Head Teacher at the school, said:

'When Millie was first diagnosed we were all very worried for her, but she returned and settled back into school life very quickly. We did make minor adjustments within the school, the teaching and wider staff all received education from the local hospital on how to help Millie manage the condition. She is a very active member of the school community and when she approached me to ask for permission to hold this awareness event I was delighted to support her – I will be ‘pinging’ my elastic band.'

JDRF has developed "Talking T1" – teens with type 1 diabetes, a free resource for secondary schools to educate teachers, pupils and parents about type 1 diabetes, in a fun and interactive way. This follows on from the success of the "Talking T1" pack for primary schools.

Click here to order your "Talking T1" pack

JDRF is delighted to announce that Webroster Ltd has raised over £700 for JDRF in an online auction to celebrate the company’s 10th anniversary.

Webroster has provided online workforce management solutions for the past 10 years, including the system issued widely in the care, security and cleaning industries to roster, manage and track staff. The auction celebrated Webroster’s 10th anniversary and ran from 10-24 October 2012. Customers were invited to participate by bidding on the 10 items that were up for auction. All items were donated by Webroster, its staff and suppliers. They ranged in value from home grown chillis to training days, a smartphone and football tickets. All items started the auction at £1 yet the highest bid was £250 for a support and development day with the Webroster team.

JDRF is a charity close to Webroster’s heart. Managing Director Nigel Gittins raised £1,760 for JDRF by cycling from London to Paris in 2010. He said:

'It is great to see so many of our customers getting involved in the auction to raise money for charity, everyone has been very generous and we are delighted to be celebrating our 10th anniversary by helping a worthwhile charity.'

Louise Ingham, JDRF Development Manager for London and South East, said:

'Thank you to all of Webroster’s fantastic staff and customers for their generosity and support for our efforts to find the cure for type 1 diabetes. Congratulations too to Webroster on reaching such an important milestone!'

A new drug that could improve the success of islet cell transplants, for people with type 1 diabetes, has just entered the third phase of clinical trials. Reparixin, made by Italian company Dompe, is an anti-inflammatory drug that may help more islet cells to survive in the days after transplant.

The phase III trial will be conducted with 60 patients across 10 centres in Europe and the USA. This is approximately half of the total number of patients who will receive an islet transplant worldwide during the period the trial will take place. The drug has already shown promising results in smaller trials, but this larger trial is designed to give a clear answer about how well it works.

The main aim of the study is to look at how effective Reparixin is at improving the efficiency of islet transplantation. The team will also assess whether people who receive Reparixin are more likely to become completely insulin independent than those that don’t receive it.

Islet transplants are not a common treatment for people with type 1 diabetes at the moment and are usually reserved for people who have severe hypoglycaemia unawareness. This is partially because transplants are inefficient - many of the cells die in the period directly after transplant. In addition, after an islet transplant, people need to take strong drugs that suppress the immune system, leaving the body vulnerable to infections.

Maebh Kelly, Research Communication Officer at JDRF said, ‘Finding ways to improve the survival of cells after transplant may mean that this treatment can be extended to more people. This research will also become important once alternative sources of islet cells are available for transplant.’

Mums Jo Dury, Helen Campling and Sabrina Dawe have teamed up to do their annual ‘The Faces that Live with Juvenile Diabetes’ calendar to raise awareness and vital funds for JDRF. 

The mums know the importance of finding a cure, as their children were diagnosed with the life-long condition. Jo’s daughter Emily,5, was diagnosed at 11 months, Helen’s daughter Ella-Mae, 13, was diagnosed aged four and Sabrina’s son Dylan, 5, was diagnosed aged 13 months. 

The calendar showcases the brave and beautiful children who live with type 1 diabetes. It will be on general sale from 14 November, World Diabetes Day, at £7.95 plus P&P with all proceeds going to JDRF.

This is the fourth year of the calendar and this year's sponsors include BabyTV and Funky Pumpers. The theme for 2013 focuses on the spirit of the Olympics and the Jubilee, celebrating the children who live so bravely with type 1.

Throughout the four years the mums have been lucky enough to work with different designers and printers, including Jen McKenzie, who has type 1 herself, as well as two of her three daughters, Harriet and Erin who were diagnosed within ten days of each other. Sharon Bowyer whose son Charlie was diagnosed at 15 months and Steve Newton, whose son Leo was diagnosed also aged 15 months 

The team is this year working with Nicola Thackeray, who donated her time for free to the calendar.

There is also a limited edition 'Peace, Love and Insulin' Christmas card on sale in packs of 10 for £4.95 plus P&P. 

The mums said:

'Raising funds for JDRF and working towards a cure is the goals for all of us. The calendar provides parents and our children with a positive focus for the year ahead and the photos are stunning! This year we have had a record number of photos submitted, 85 brave and happy children's faces, who we met via the Children with Diabetes UK group.'

Last the team raised over £5,000 for JDRF and they hope to do the same again.

You can buy your copy of the calendar at http://www.funkypumpers.com/

Report finds that ‘progress in delivering the recommended standards of care and in achieving treatment targets has been depressingly poor.’

The Committee, which scrutinises public spending and focuses on value-for-money criteria based on economy, effectiveness and efficiency, this morning issued a damning report on the state of care for adults living with diabetes.

MPs found that NHS accountability structures have failed to hold commissioners of diabetes services to account for poor performance. And that standards of care, although improved mean that only half of people with diabetes, and less than one third of people with type 1, are getting all their nine care processes every year.  In addition, fewer than one in five people are achieving HbA1C, blood pressure and cholesterol targets.

The Committee warned that unless significant changes are made, the health burden on people with diabetes, and the cost to the NHS, will continue to grow.  We support calls for the Department of Health and NHS to make healthcare for diabetes a priority, and we continue to work with Government to improve access to treatments and technology for type 1 diabetes, and to increase funding for medical research to cure, treat and prevent the condition.

Get involved with JDRF’s campaigning work

Janey Rossiter, of Modbury in Devon, along with her family and friends will be running the Plymouth 10k on 4 November to raise money and awareness for JDRF. Janey’s husband Richie, 42, was due to run the Plymouth Half Marathon in May but passed away very suddenly, so in his memory friends, family and Richie’s workmates are taking part in the Plymouth 10k as a fitting way to remember him. Along the way, ‘Richie’s Racers’ hope to raise money for JDRF, as one of Janey and Richie’s daughters, Dani (age 4), has type 1 diabetes.

The 10k run starts at Princess Street, in the city centre at 8.15am and is a great opportunity to raise awareness for type 1 diabetes.

Janey comments:

‘Richie was a great husband, a brilliant dad, a gentleman and a friend to SO many. Our daughter was diagnosed with type 1 diabetes last year and so Richie had planned to run the Plymouth Half-Marathon in aid of JDRF but it wasn't to be. It seems fitting that his work mates, friends and I run the Plymouth 10K for him in his memory instead.’

Richard Horton, Richie’s ex colleague at the Land Registry at Seaton Court in Kingsbridge, Plymouth, decided to run the 10k in honour of Richie. The idea snowballed from there with nearly 70 runners signing up for the event. As Richie was a lifelong supporter of Queen’s Park Rangers, the Land Registry team will be running in Queen’s Park Rangers strip which has been kindly donated by the club.

Hannah Gripton, JDRF Regional Fundraiser for the Midlands, commented:

‘It’s an incredibly difficult time for the family and I’m very sorry to hear of Richie’s loss. It’s evident that at such a tragic time, the family are still so dedicated to JDRF and supporting us to find the cure. We are entirely grateful for their efforts and wish the team the best of luck for the run.’

To donate to Richie’s Racers, please visit: http://www.justgiving.com/richies-racers

JDRF is delighted to announce that Chris Southwell has been named as a World Diabetes Day Champion by the International Diabetes Federation. Chris is recognised as one of the UK’s leading professional free rise snowboarders, and is an ambassador for JDRF.

Chris was unexpectedly diagnosed with type 1 diabetes eight years ago, in his early twenties. Instead of letting the diagnosis hold him back, Chris decided to use his experiences and positive outlook to help others. He does a number of lectures around the world on living as professional extreme athlete with type 1 diabetes, and has spoken at JDRF events.

Chris said:

'I hope that my life experiences will motivate and inspire other people, and particularly young people, which is the reason why I am an ambassador for JDRF and I strongly support the important work it does to find the cure for type 1 diabetes and its complications.  I believe that if you have the right control, determination, positive outlook and attitude you can achieve even your wildest of dreams… I am living mine!'

His latest venture is being launched soon: 7C7A – 7 challenges in 7 continents. These events are:

1. July 2013 – Iron Man Zurich (Europe)
2. October 2013 - 100 miles Himalaya stage race (Asia)
3. January 2014 – Trans Andre Challenge (South America)
4. May 2014 – Climb Mount Kilimanjaro (Africa)
5. November 2014 –Antarctic Ice Marathon (Antarctica)
6. February 2015 – Coast to Coast (Australasia)
7. July 2015 - New York to Miami (cycling) (North America)

There will be opportunities to join him in two of the challenges: climbing Kilimanjaro and cycling New York to Miami which will be set up into stages so people can decide how far they would like to bike.

The International Diabetes Federation explained why they selected Chris as a World Diabetes Day Champion:

‘To many young people Chris is inspirational in his untiring work for type 1 diabetes. How he copes with his career, which does not exactly go hand in hand with injecting insulin four times a day in extreme circumstances, is certainly good reason for Chris being a WDD Hero!’

To find out more about the 7C7A challenge, click here.

To find out more about joining Chris on the 7C7A challenge, contact Adele Claase at events@jdrf.org.uk or on 020 7713 2030.

To mark World Diabetes Day on 14 November, JDRF is kick starting two weeks of fundraising in the office with a blue quiz.

For World Diabetes Day this year we are focusing on raising awareness of type 1 diabetes in schools. Just £20 would mean we could reach 2,000 secondary school children with information, and offer them the opportunity to understand type 1, and support the children in their school who live with it.

Our goal is to raise £35,000, if you would like to donate towards this or to plan your own fundraising, find out more on our WDD page. 

Over the next two weeks JDRF staff will be getting involved in a variety of blue related activities from a blue bake sale to a blue treasure hunt, from blue hat/hair day to blue food for lunch.

Follow us on Facebook or Twitter to be kept up to date with all our activities.  And don’t forget to tell us all about what you’re planning.

So to start you off, why not join in with our blue quiz? 

1. Blue litmus paper turns red under what conditions?

2. In which country does the Blue Nile meet the White Nile?

3. Which cocktail is made of gin or vodka, with lemonade, ice and blue curacao?

4. Who directed the film Blue Velvet?

5. What are the first names of the ‘Blues Brothers’ in the 1980 film?

6. In what year did singer Joni Mitchell release her album, Blue (Closest year wins bonus point for exact date)?

7. In what country is the presidential residence called The Blue House?

8. Who scored a number 1 hit with Blue (Da Ba Dee) in 1999?

9. What is the name of the blue fish in Finding Nemo?

10. Stilton is a type of blue cheese, but in which county is the village of Stilton?

11. In what year was the first Blue Peter aired? (Closest answer wins, bonus point for exact date)

12. What colour are a Blue-Jay’s feathers?

13. What was the first single the band Blue released?

14. A Blue Whale’s tongue weighs roughly the same as which other animal?

Well done to Mike, our Database Manager, for winning the blue quiz. 

Click here to download the answers. 

JDRF has launched the biggest ever international initiative to understand the genetics of kidney disease in people with type 1.

 The JDRF Genetics of Diabetic Nephropathy collaboration will provide three years research funding worth more than $7 million. The collaboration includes research teams from around the globe including the UK, US, Canada, France, Denmark, Finland and the Republic of Ireland.

The UK arm of the study will be led by Dr Peter Maxwell from Queens University Belfast. Dr Maxwell and his team will try to understand how the genetic information translates to clinical symptoms of the condition. The Republic of Ireland arm will be led by Dr Catherine Godson from University College Dublin. Her team will be involved in the analysis of the data generated during the study.

Diabetic kidney disease can occur as a long term complication of type 1 and good blood glucose control can reduce the risk of developing it. Interestingly, some people who have had type 1 for a long time do not develop kidney problems whereas others who have had type 1 for a shorter length develop kidney problems early.

Previous research has indicated that genetic factors play a role in the risk of developing diabetic nephropathy, but scientists do not yet have a full picture of the specific genes involved. This project aims to get a clearer picture of the genes involved.

Researchers working on the project will look for genes that differ between people with type 1 who do or do not have diabetic nephropathy and identify genes which predict how quickly a person with type 1 may develop kidney problems.

Maebh Kelly, Research Communication Officer at JDRF said, ‘The aim of this collaboration is to build on what researchers already know about diabetic kidney disease. By working together and pooling knowledge and resources, scientists will be able to learn more about why some people with type 1 are more likely to develop kidney problems than others.’

Find out how you can support our research programme

Steve Paxton of Nuneaton and Nigel Hammond of Milton Keynes are both fathers of children with type 1 diabetes. They have composed a song, Innocent Eyes, which will be released on CD and as a download to coincide with World Diabetes Day on 14 November to raise money for JDRF. 

Steve's children Francesca, nine, and Jacob, seven, were diagnosed with type 1 diabetes aged six and five. Steve wanted to use his lifelong interest in the music business to write these meaningful lyrics about a father’s perspective of having a child with type 1, and Nigel developed the accompanying music.  

Steve commented: 

'I have two children with type 1 diabetes, and am naturally keen to raise money for JDRF. We started this project as a result of a video that some mothers of type 1 children have made reciting a poem called 'A Mother’s Anthem'. Someone asked if there was a father’s version and if not, suggested that one of the dads might like to take up the challenge. I used to write lyrics and decided to put my skills to use, and once I’d finished I thought that it could be taken one stage further and be developed into a song. I was then put in touch with Nigel, who writes music in his spare time, and ‘Innocent Eyes’ was the result. We’re delighted with it and really hope that people will buy the track to help us raise as much money as possible to support research into type 1 diabetes.'

The duo plan to release Innocent Eyes on CD and as a download. The video is currently being produced and vocals being laid down. The project is on track to launch on World Diabetes Day, 14 November.

Hannah Gripton, Fundraiser for the Midlands said:

'We are really grateful to Steve and Nigel for their thoughtful fundraising activity. The song is a personal message that reflects Steve’s story and we know many people will be able to relate to this. There are 29,000 children living with type 1 diabetes and JDRF is determined to find the cure.'

Duxford Airfield’s Imperial War Museum was the setting for Flying with Diabetes Day last Saturday. The event was organised by Douglas Cairns, former RAF pilot instructor and holder of multiple aviation speed records, for JDRF. The event, supported by Sanofi, Dexcom and Medtronic, attracted 150 air enthusiasts keen to meet Douglas, who has lived with type 1 diabetes since 1989. He recently added a new record to his collection after leading a UK Diabetes Formation Flight along with five other pilots with diabetes - setting a new national formation speed record. 

The day featured talks from record-setting pilots with diabetes, plus Colin Roland, a marathon runner and torch bearer during the Olympic celebrations, and cyclist Melissa Ford, who both shared their type 1 diabetes stories.  There was also a presentation by leading Endocrinologist and Senior Lecturer at Bristol University, Dr Rob Andrews.

 Mad Science provided entertainment for younger children, and visitors also had the chance to walk through the cabin of a Concorde supersonic aircraft. 

Organiser Douglas Cairns said:

'I wanted to organise a day that brings my two passions together, flying and raising awareness of type 1 diabetes, in the hope that one day JDRF will find the cure. Seeing people chatting and asking questions at the exhibitor stands, and people's positive reactions to the talks, particularly Colin Rowland's, were the high points for me.'

Caroline Horwood, Diabetes Division Director at Sanofi said:

'We were delighted and proud to be able to support Douglas’ Flying with Diabetes event. Sanofi is a company that is committed to working to make a difference to the lives of people with diabetes and those that care for them, and we are fully aligned with raising awareness of type 1 diabetes with JDRF at this exciting and innovative event.'

For further information about Flying with Diabetes Day please visit www.flyingwithdiabetes.com

NHS Diabetes has this week launched a new, free e-learning tool called Safe Management of Hypoglycaemia. This is an online training course that will help people with type 1 safely manage hypos.

The module is designed primarily for healthcare professionals but is also suitable for adults with type 1 and families and carers of adults with type 1. It takes about half an hour and can be done in more than one sitting. 

The training focuses on the key elements of managing hypos:

• What is a hypo
• Signs and symptoms
• Treatment of hypos
• How to avoid hypos
• Driving and hypos

The 2011 National Diabetes Inpatient Audit reported that the number of inpatients who had at least one hypoglycaemic episode has increased from 21.7% to 23.4% since the 2010 audit. This module aims to reduce the number of people with type 1 who experience hypos.

Hypos occur when blood glucose levels become too low and are one of the most common and potentially severe side effects of insulin therapy.

Register for the e-learning module

If you have any problems email info@healthcareea.co.uk

Gloucestershire writer Debbie Young has found a new way of using her specific talents to fundraise – she has pledged 25% of the author’s royalties from her new book to JDRF.

JDRF is a cause especially important to Debbie because type 1 diabetes affects both her husband and her only child. Gordon was found to have type 1 diabetes not long after they met in 2000, but this did not prepare them for the shock of three-year-old Laura’s diagnosis in 2007.

'I was devastated,' says Debbie. 'It was like a bereavement for my daughter’s perfect health. But as soon as I heard about the amazing research being funded by the JDRF, my depression started to lift. It was incredibly therapeutic to realise that there was something tangible I could do to help find a cure: I could raise funds. The first JDRF’s Type 1 Discovery Day I went to was a revelation to me and I remember walking home from the conference feeling totally inspired.

We immediately began the usual course of fun runs, walks and charity sales, but when I was commissioned to write a book, I realised that this could be a really good new way to raise more money without having to ask my family and friends for sponsorship.'

Published this month by SilverWood Books, Sell Your Books! is a book promotion handbook for self-published authors. It draws on Debbie’s long experience in journalism, public relations and marketing and is already earning excellent reviews, being hailed as a 'must-read' for authors everywhere.

'I’ve been amazed at how many people have told me they’re interested in buying a copy because either they are writing a book or they know someone who is writing a book!” Debbie reports, who runs her own business for promoting authors, Off The Shelf Book Promotions

'I was also very touched when one of the book’s first buyers, a lovely historical novelist, insisted on donating her change to JDRF. Laura came to the book launch party with me and I didn’t realise until afterwards that having her pump clearly visible over her party dress must have added extra poignancy to my speech about JDRF.

'My publisher, SilverWood Books, has been very understanding, agreeing not only to write the donation into my contract but also allowing me to add a paragraph about JDRF beneath the biographical blurb on the front page, including the website address. This means my book will raise awareness as well as funds.'

Debbie’s writing ambitions do not end with this book. She’s now working on a collection of short stories called Tuning In, which will be published in 2013, again with a share of the royalties to be pledged to JDRF. She also writes a personal blog about family life which frequently includes posts to raise awareness of diabetes and funds for JDRF – watch out for Debbie’s blog on World Diabetes Day.

SilverWood Books welcomes enquiries from any individuals or groups interested in publishing books to raise funds. More information can be found at www.silverwoodbooks.co.uk; email enquiries may be sent to helen@silverwoodbooks.co.uk. 

On Saturday a jumble sale was held in Wortham Village Hall to raise money for JDRF, along with two other charities. The event was inspired by Madeleine, 14, who has had type 1 since early 2011.

Madeleine’s parents Sarah and Matthew said:

‘Since Madeleine was diagnosed with type 1 diabetes, JDRF has been a cause close to our hearts. More research needs to be done to find the cure, and that's why we support JDRF.’

They were joined by seven other local families who helped to organise the jumble sale. The sale started at 10am on Saturday 20 October, but some people were so keen they queued from 8.30am. About 400 people attended the sale, and the families were delighted by how far people travelled to support the sale.

Madeleine ran a tea stall during the morning and raised over £50 from cakes kindly made by the family’s new neighbours and refreshments donated by Morrisons supermarket. So far the sale has raised over £700 for JDRF, East Anglian Children’s Hospital (EACH) and the local Air Ambulance.

The families involved would like to thank everyone who came and supported the event on the day, and the many people who helped by donating items. If you were unable to attend the event but would still like to donate some money, visit www.justgiving.com/madsgaragesale

Image taken from article in Diss Express.

We are very proud to announce that JDRF T1 Youth Ambassador Zoe Scott has been presented with the People’s Award at the 2012 Quality in Care Diabetes Awards. The award recognised her work in setting up Hedgie Pricks Diabetes, an organisation raising awareness of and helping to tackle the psycho-social challenges faced by young people with diabetes.

The Quality in Care Diabetes Programme is supported by Diabetes UK, NHS Diabetes and Sanofi, and recognises good healthcare practice in diabetes in the UK. It comprises both an awards event and subsequent opportunities for finalists to explain why their efforts were successful to a wider healthcare audience. This sharing of best practice aims to ensure that successful initiatives are more widely adopted across the UK.

On the night JDRF was highly commended for its “Talking T1” Schools Programme. The programme is supported by Lilly, and was recognised as a project facilitating new or improved diabetes services through an industry/charity partnership.

Other awards included the best early detection and prevention initiative, presented to Ipswich NHS Trust for its Ipswich Touch Test to screen for neuropathy at home, and the outstanding educator in Diabetes award was given to Heather Daly, a nurse consultant at University Hospitals Leicester.

Simon Mitchell, Community Relationship Manager at JDRF said:

'I am very proud that JDRF has been recognised for its Schools Programme alongside such fantastic diabetes healthcare initiatives across the UK. And well done Zoe Scott for being acknowledged for her efforts to highlight the psychological and social effects of diabetes on young people. This is a cause that is important to many of our T1 Youth Ambassadors and her work will be an inspiration for all.'

This Saturday (20 October) two local mums will be hosting the Sugar Plum Ball at the Castle Hotel, High Street, Windsor to raise vital funds to help JDRF. Enterprising mums Dawn Pritchard and Leyla Watson were spurred on to raise not only funds but also awareness after both of their sons were diagnosed with type 1 diabetes at the age of eight.

Dawn and Leyla hope to raise £20,000 and have been busy planning and encouraging people to come and have some fun while helping JDRF to find a cure for type 1 diabetes.

Dawn told us:

'In November 2008, both my son Cameron and Leyla’s son Samuel were sadly diagnosed with type 1 diabetes. They were only eight. From that moment our entire families’ lives changed for ever. We could not have known when our baby boys were born that eight years later they would develop this devastating, incurable disease for no obvious reason. On the outside, children with type 1 diabetes look like every other kid. They play sport, go to school and have fun with family and friends, but on the inside they face a lifelong struggle as their pancreas no longer produces the insulin they need to keep them alive. People think injectable insulin is a cure. It’s not. It’s just life support. It allows us and them to manage their disease but not control it.'

Leyla continued:

'Every minute of every day is balancing act of measurements and actions – involving activity, food, emotions and insulin. Diabetes doesn’t take holidays; it doesn’t stop for sleep or celebrations. Cameron and Samuel can’t be carefree like other children. They can’t run on a football pitch and start playing, they have to do a blood sugar test first and take insulin every time they want to eat anything. They have to do at least seven fingertip blood tests every day and have multiple injections just to stay alive. Since they were diagnosed four years ago, they have each done around 10,220 finger prick tests and around 7,000 injections/pump insertions. They are very brave but unless a cure is found they will have to go through this their entire lives.'

The money raised will help to support vital research into finding the cure for type 1 diabetes and its complications.  The chronic condition, which can strike suddenly and without warning, affects an estimated 400,000 people across the country, including 29,000 children.

Nicole Gerrard, JDRF’s Senior Fundraiser for the area, said:

'It’s people like Dawn and Leyla who really help to make a difference. Without this kind of generosity we wouldn’t be able to do what we do and I’m entirely grateful for their help.'

If you would like to support, sponsor or attend the Sugar Plum Ball, please email sugarplumdinnerdance@hotmail.com

This weekend Kerry Katona (pictured) attended Pop4Diabetes, an annual event organised by JDRF supporter Iris Board. The night was a chance to raise awareness of type 1 diabetes while celebrating some truly inspirational children and was hosted at the Marriot High Cliff Hotel, Bournemouth.

Over 200 guests enjoyed a champagne reception, followed by a three course meal and an auction at the fundraising event. Iris’ son Shane, 23, was diagnosed with type 1 diabetes aged 10 years old and performed his new song ‘Believe’ on the night. The single will be released on World Diabetes Day (14 November) and profits will go to JDRF.

Kerry Katona awarded the ‘Child of Courage’ awards to children who have overcome the life changing diagnosis of type 1 and said:

‘I was delighted to be asked to attend such a fantastic event. I enjoyed meeting the children at Pop4Diabetes and hearing more about their type 1 stories. I was amazed at how many people in the UK live with type 1 diabetes and what it entails to ensure that their type 1 in kept under-control. JDRF is an amazing charity and I would strongly urge people to donate to this great cause, in order for JDRF to one day find a cure for type 1 diabetes.’ 

The awards were split into three categories; junior for children aged between 5-11 years, senior for children aged between 12-16 years and the Christopher Hall Memorial Award which was introduced two years ago to celebrate the life of six year old Christopher. His family were on hand to present the award alongside Kerry.

For further information about Pop4Diabetes, please visit www.pop4diabetes.co.uk or for more information on JDRF and type 1 diabetes www.JDRF.org.uk

Earlier this year two fundraising families from Cardiff went all out for us, organising the Mumbai Ball and seeing JDRF become charity of the year for the Carten100 group. We are delighted to announce that today we received a cheque for £85,293.98. This will go towards vital research, including projects at Cardiff University, in order to help find a cure for type 1 diabetes.

The Ridgwell and Burch families presented the cheque earlier this morning at the Sports Council of Wales, Sophia Gardens, Cardiff. It was the enthusiastic fundraising efforts of both families that made the final figure raised reach such a staggering amount, and JDRF was delighted to be able to thank both families at the cheque presentation.   

Both families know first-hand the importance of finding the cure, as the Ridgwell’s daughter Katie was diagnosed with type 1 diabetes three years ago when she was nine years old. Lis Burch’s two children also live with the condition. Her daughter Ismay was diagnosed in 2006 aged eight years old, along with her brother Marcus, 17, who has been living with the condition for the past nine years.

Lloyd Ridgwell joined Peter Palmer, Dave Stealy, James Lewis among others in delivering the Carten 100 in May this year. A record breaking 650 cyclists took part, starting their journey from Cardiff and ending up in Tenby. The Carten 100 Organising Group was delighted at the number of riders who participated in the 2012 event, generating over £71,000 for JDRF. Peter Palmer said:

'We were delighted that the 2012 event was such a success and the event is growing in popularity each and every year. A huge heart-felt thanks to all our sponsors, who collectively donated £10,000 to the cause. A special thank you to the companies that provided the van and bike support. Finally, the biggest thanks of all goes to everyone who trained and dedicated their time to fundraise and crossed the finish line.'

The Mumbai Ball was organised by Janine Ridgwell and Lis Birch to support the Carten100 bike ride. It was held a month earlier in April at the Cardiff Coal Exchange, and saw over 300 enthusiastic supporters enjoy a wonderful evening of dancing and dining. The night raised over £13,000 for JDRF, through ticket sales, an auction and a prize draw. 

Lloyd Ridgwell said:

'On behalf of my family, I am entirely grateful to our friends, family and strangers who supported us for dedicating their time and efforts to such a great cause. We are firm supporters of JDRF. We heard about the charity, via the hospital, when Katie was first diagnosed and appreciated the help we initially received and still do receive from them. We will continue to fundraise in order to help JDRF one day find the cure for Katie and so many others living with type 1.'

The Carten 100 was generously supported by MyLife Diabetes Care

The current recommended treatment for DMO is laser surgery, which can slow down or stop further damage occurring but is not usually associated with an improvement in vision. Current research indicates that Lucentis is effective in treating DMO and, significantly, that it meets an unmet need for patients who do not respond well to the current standard laser treatment.

JDRF supported the early development of Lucentis through an innovation grant and has been involved with supporting its progress through NICE.  We are pleased that the drug is now available to some people with DMO.

Sarah Johnson, Director of Policy and Communications commented ‘This decision will help people with type 1 who are in danger of losing their sight and we hope that this is the first step in the drug being more widely available to people with DMO.

Over 460 dedicated fundraisers came along to Victoria Park, London on Sunday for the final JDRF Walk of the season. Walk to Cure Diabetes London has generated £25,000 so far, with over £225,000 raised across all this year's Walks. These funds will go towards supporting vital research to help JDRF one day find the cure for type 1 diabetes.

On the day, hundreds of walkers and runners took on the route around Victoria Park, raising money and awareness for JDRF. Among the walkers was New Cross resident Eleanor Lotsu, 12, and family (pictured with Rushanara Ali MP). Eleanor was diagnosed with type 1 diabetes when she was just seven years old. Eleanor’s mum Louise Shepherd told us: 

‘We thoroughly enjoyed the Walk and it was great to see so many people there all raising awareness and money for such a great cause. We have taken part in the walk several times and are delighted that we can do our bit to help JDRF to hopefully one day fine a cure for Eleanor.’

Before the Walk and Run kicked off, participants enjoyed a warm up session led by members of Fit for Sport, a Chiswick-based healthy lifestyle activities provider. Stephanie Fanning then led an energetic Zumba session to get everyone limbered up and ready to Walk and Run.

Children were treated to face painting, giant games and circus skills training in the Children’s Tent, while Fit for Sport led an inflatable Olympic games outside, featuring Olympic favourites such as the sprint, relay, long jump and javelin. Refreshments were provided by Jacob's Ladder Farm and the Pavilion Cafe. For the first time in its 17 year history, Walk to Cure Diabetes London also hosted stalls selling crafts and creative goods in the Walk Village.

Rushanara Ali, MP for Bethnal Green and Bow, showed her support by attending the event and giving a speech. Speaking after the event, Rushanara told us: 

’I was delighted to open JDRF’s Walk to Cure Diabetes at Victoria Park on Sunday. The work they do is so important, not least to the over 1,000 people right here in Tower Hamlets living with type 1 diabetes.  I know that JDRF works hard to tackle type 1 diabetes. The funds raised will support groundbreaking research to help cure, treat and prevent type 1 diabetes.’ 

JDRF would like to thank everyone who attended and supported our final Walk to Cure Diabetes 2012 event. It has been a fantastic Walk season with over £225,000 raised so far. We look forward to stepping out for the cure with you again in 2013.

Click here to view photos from the day. We will be adding more over the next few days - watch this space!

Living Cell Technologies has announced the results of their latest human trial of encapsulated islets. 

The trial, which took place in New Zealand with support from JDRF, aimed to test if transplanting encapsulated islets is safe, and to determine what ‘dose’ or number of transplanted islet cells would be the most beneficial to people with type 1.

The researchers reported few side effects of the treatment and a significant reduction in hypoglycaemia unawareness in people with type 1 who received a transplant. People who received the treatment also reported an improvement in quality of life.

Islet encapsulation is a new way to protect transplanted islet cells in people with type 1 diabetes. The islet cells are encapsulated in a protective bubble that has tiny holes to let insulin out and glucose in (as shown in illustration). These holes are too small for the cells from the immune system to enter, so the islets are protected from both transplant rejection and the reaction that causes type 1 in the first place.

The promising results of this trial will allow the researchers to apply for approval to start a phase IIb trial. A phase IIb trial will allow the researchers to test their technology on a larger group of people to gather more data on how effective it is at restoring insulin production.

Maebh Kelly, Research Communication Officer at JDRF commented, ‘Islet encapsulation is a very exciting topic at the moment and the results of this trial are encouraging. However, this is an early phase trial and the number of people involved was low. Larger studies will now be carried out to determine just how effective it is’.

Today at the EASD annual meeting, JDRF held a joint symposium with the EASD on beta cells. During the session, Dr Simona Chera from the University of Geneva in Switzerland presented her research on alpha cells that can turn into beta cells.

Dr Chera and her team have found that in adult mice that have had type 1 diabetes for a long time, the alpha cells (that usually make glucagon) can turn into cells very much like beta cells, making insulin in response to changing glucose levels. The team began by monitoring the alpha cells after the beta cells had died and found that a long time after the loss of beta cells, some alpha cells began to turn into insulin producing cells.

Interestingly, Dr Chera reported that the changing of alpha cells into beta cells was only found in adult mice. While younger mice do also regenerate new beta cells after the development of type 1, they do not come from alpha cells. In fact the team found that regenerated beta cells in younger mice came from less specialised pancreatic cells in the same way that beta cells are normally made. 

In the same session, Dr Patrick Collombat from INSERM in France presented his work that found that the differentiation of alpha cells into beta cells is caused by a protein called Pax4. He found that altering the levels of Pax4 in mice caused more beta cells to develop.

Maebh Kelly, Research Communication Officer at JDRF commented: 'Alpha cells are found next to beta cells in the islets of the pancreas, but they are not usually destroyed in type 1 diabetes. Understanding the relationship between alpha cells and beta cells may help scientists find new ways to help the body to produce more beta cells.'

This week you may have seen reports in the media that the number of cases of diabetes in the UK is expected to reach 4.4 million by 2020.

The media focuses primarily on the increase of type 2 diabetes. However, the incidence of type 1 diabetes is also rising, and this cannot be halted by lifestyle factors such as changes to diet or exercise. There is currently no way to cure or prevent the condition.

Our report Facing Type 1 Diabetes highlighted that in 2010/11 the direct and indirect cost of type 1 diabetes to the UK was £1.9 billion. Incidence of type 1 diabetes is growing at about four per cent each year, and the report estimated that 650,000 people in the UK will live with the condition by 2036. This could cost the UK £4.2 billion each year, and will continue to rise until we find the cure.

JDRF exists to fund the world-class research that is needed to cure, treat and prevent type 1 diabetes. We believe that the only way to reduce the cost burden of the condition is to invest in research to find the cure – find out how you can get involved.

Today at EASD Professor Noel Morgan, from the Peninsula Medical School in Plymouth, presented his research on the role of viruses in type 1 diabetes.

Professor Morgan and his team analysed pancreatic samples taken from people who had type 1 and compared them to samples from people who did not have type 1. They looked for the presence of enteroviruses, which are a large family of viruses that include the common cold 

Over 80% of the samples from people with type 1 had evidence of virus proteins in the remaining beta cells. These viral proteins were not found in any other islet cell. Only 30% of the samples taken from people who did not have type 1 showed evidence of viral infection in beta cells.

Professor Morgan and his team think that in some people, enteroviral infection can trip beta cells into a self-destructive mode – which is good news in the short term, as the virus is destroyed along with the cell. But once the viral infection is gone, the beta cells remain in this destructive mode, meaning that when a rogue immune cell attacks the beta cell, the cell dies straight away, instead of triggering the normal protective mechanism that cells usually employ in these scenarios.

In the same session, Professor Matthias von Herrath presented findings from his research team in California. Interestingly, his work has led to the discovery that some viral infections may have a protective effect against type 1 while others may be detrimental.

His research showed that while some strains of enterovirus seem to be associated with the development of type 1, others may protect against the condition. He found that infection with a low dose of some strains of enterovirus actually improved the immune system’s ability to fight off other infections in the future. It caused an increase in the number of regulatory T cells that were present in the immune system.

In type 1 diabetes, the balance between regulatory and killer T cells is out of kilter, with more killer cells being produced. An increase in the number of regulatory T cells would stop this imbalance occurring.

This research lends support the theory that the immune system gets better the more it is used. Since our environment is a lot cleaner than it used to be, our immune systems’ may not be getting enough practice to allow it to fight things like type 1 diabetes.

Research Communication Officer Maebh Kelly said, ‘There is a lot of research at the moment into the causes of type 1, and how we might prevent it. All of this work on viruses adds to our understanding of the way the immune system works to protect us, and how this goes wrong to lead to type 1 diabetes. But this morning’s presentations show that the picture of the role viruses may play in the development of type 1 is far from clear cut.’

Over the past few weeks JDRF has held three fantastic Walk to Cure Diabetes events, raising over £200,000 so far to support research into the cure. This Sunday is the final Walk to Cure Diabetes at Victoria Park, London – don't miss your final chance this year to step out for the cure.

Rushanara Ali, MP for Bethnal Green and Bow and Shadow International Development Minister, will be kick starting this year’s Walk to Cure Diabetes London at Victoria Park. There will be a 5km walk and a 10km run, as well as a shorter walk that’s perfect for little legs and pushchairs. This year is also the first year when the Walk Village will showcase stalls selling creative crafts, along with bouncy castles, face painting and refreshments. And don't forget your (and Rufus') fancy dress outfits - this year's theme is Teddy Bears' Picnic.

To get the crowd pumped up warm up acts will be provided by Fit for Sport, the UK’s leading healthy lifestyle activities provider plus instructor Stephanie Fanning will be doing some zumba moves.

Dean Horridge, CEO-Founder of Fit for Sport, will be supporting the cause. Dean is an ex-PE teacher at a prep school in Kensington, and knows first-hand about type 1 diabetes having been diagnosed with the life-threatening condition in 2001. He was fully aware of the symptoms, as his grandmother, father and his twin brother, plus Dean’s two brothers all have type 1. Dean manages his diabetes through an insulin pump which he has had for the past six years.

 Dean told us:

'Having type 1 myself, I wanted to support JDRF as it’s a great charity which is passionate about finding a cure. I try to manage my type 1 as best as I can, as I’ve seen first-hand what happens if you don’t - my father lost his life due to complications and bad management of the condition. I am a strong believer that you should control your type 1, instead of it controlling you.It’s not the end of life - it can be managed with education, awareness and individual/family commitment.'

New Cross resident and Haberdasher Aske High School pupil Eleanor Lotsu (pictured), 12, will be taking part in this year’s Walk. She was diagnosed with type 1 diabetes when she was seven years old and is the only one in her family to have the life-threatening condition. Eleanor will be joined by mum Louise Shepherd, who said:

'Eleanor can sometimes find coping with type 1 diabetes difficult, but she refuses to let it get in the way of her enjoying life to the full and being able to do what she and every other teenager girl wants to.'

There is still time to step out for the cure at Victoria Park this Sunday - register now. You can also register on the day - click here to download our information pack with maps, schedule and information about the day.

The annual meeting of EASD the European Association for the Study of Diabetes is being held in Berlin this week. This is a chance for researchers to showcase the latest diabetes research including the latest and most advanced continuous glucose monitoring (CGM) technology.

Senseonics Inc. have a poster at the event detailing their latest research into an implantable glucose sensor.  They have developed a tiny chip about 3mm in length that can be implanted under the skin in the arm. When the chip comes in contact with glucose, it sends a fluorescent signal to a ‘reader’ that is worn as an armband.  The implantable sensor is designed to work for six months.

The armband reader can then send the glucose readings to a smartphone app the team have developed or the readings can be downloaded to a computer.  The app also allows the user to enter data on what they have eaten or how much insulin they have taken.

The team have just completed a small pilot study with of their new technology with only 12 participants so must now run a larger trial to test how well it works among a larger group of people before it can be approved for sale. 

Dexcom are also presenting the results of a trial of their latest CGM G4 Platinum this week. In this trial they compared their new system to their current product Dexcom SEVEN PLUS.  

The G4 Platinum sensor was shown to be more accurate than the SEVEN PLUS, had less variability between individual sensors and had fewer interupptions in the CGM readings. However, the study does not compare the G4 Platinum to any other CGM on the market.

Nearly 500 dedicated fundraisers took part in Walk to Cure Diabetes South at Manor Farm Country Park, on the 30 September. JDRF would like to thank all the participants and supporters who dedicated their time and made it such a fantastic day. The Walk has generated £20,000 so far which will go towards vital research to help JDRF one day find a cure for type 1 diabetes.

The Walk attracted many family walkers from near and far, including Southampton residents Chris and Sam O’Donnell from Sholing who took part, along with sons Connor, 7, and Kian, 5 (pictured). They have first-hand experience of type 1 diabetes, as Kian was diagnosed just last year. His auntie, Jodie, also has the life-threatening condition and was diagnosed 11 years ago aged six years old.

Sam said:

'It was ironic that at last year’s Walk we were doing it on behalf of Jodie and literally a few weeks later Kian was diagnosed. We thoroughly enjoyed the Walk and it was great to see so many people there all raising awareness and money for such a great cause. We have taken part in the Walk several times and are delighted that we can do our bit to help JDRF to hopefully one day find a cure for both Jodie and Kian, plus all the other 400,000 people in the country living with type 1.'

Nicole Gerrard, Southampton Fundraiser for JDRF said:

'We would like to thank each and every one of you who took part in this year’s event and we hope everyone enjoyed it as much as we did. Without our supporters, it really wouldn’t be possible to do what we do best. We would like to thank our main sponsor Ford for their involvement and generosity as it has been invaluable and our media sponsors the Southern Daily Echo and Hampshire Chronicle for their support.'

The Southampton event was part of a series of Walks including Walk to Cure Diabetes Scotland in Aberdeen on 16 September and Walk to Cure Diabetes Midlands at Drayton Manor Theme Park on 30 September. The final event will be Walk to Cure Diabetes London, taking place at Victoria Park on 7 October.

Over 700 dedicated fundraisers took part in Walk to Cure Diabetes at Drayton Manor Theme Park on Sunday. JDRF would like thank all the participants and supporters who dedicated their time and made it such a fantastic day. The Walk has generated £30,000 so far which will go towards vital research to help JDRF one day find the cure for type 1 diabetes.

This year's Walk was the thirteenth annual Walk to Cure Diabetes event in the area. It attracted many family walkers from near and far, including Derby residents Carly and Paul Wheeler who took part along with 25 others friends and family members ranging from 2 months to 56 year olds (pictured). Their four year old son, Finlay (Finn) was diagnosed only this year in April and is one of 29,000 children in the UK to live with type 1.

Carly said:

'We thoroughly enjoyed the Walk and it was great to see so many people there all raising awareness and money for such a great cause. We have taken part in the Walk several times and are delighted that we can do our bit to help JDRF to hopefully one day fine a cure for Finn and all the other 400,000 people in the country living with type 1.'

Tamworth residents Lisa and Nick Warren-Brownhill also came along with their four year old daughter, Jaici, who was diagnosed with type 1 in June 2011. Tamworth MP Chris Pincher showed his support by attending the event. In his speech he remarked:

'I was honored to open JDRF’s Walk to Cure Diabetes at Drayton Manor Theme Park on Sunday. I know that JDRF works hard to tackle type 1 diabetes, an illness which is both life-threatening and life-long. The funds raised will go towards funding research to help treat, prevent and hopefully cure type 1 diabetes.'

The Southampton event was part of a series of Walks including Walk to Cure Diabetes Scotland in Aberdeen on 16 September and Walk to Cure Diabetes South in Southampton on 30 September. The final event will be Walk to Cure Diabetes London, taking place at Victoria Park on 7 October.

Congratulations to Joe Bishop, aged 11, who is our September Morph of the Month!

We love the pose, and can't wait to see Joe "morphin" around at Walk to Cure Diabetes London on 7 October 2012.

JDRF receives a donation with the purchase of every blue Morphsuit, so not only can Joe show off his cool new look to friends, he is also supporting our vital work to cure type 1 diabetes. As Morph of the Month, Joe wins two Morphsuits of his choice so that he can continue "morphin" on any occasion.

There is still time to buy a blue Morphsuit, so don't miss out! Use this code morphjdrf online to receive a 25% discount and ensure a donation is made to JDRF - click here to buy an adult suit and here to buy a kids suit.

Participating in a Walk to Cure Diabetes event? Why not wear a Morphsuit? Lots of lovely supporters did at Walk to Cure Diabetes Scotland and they had a great time - check out the photos on our Morph gallery.

Going blue for World Diabetes Day? You can't get more blue than when you're in a Morphsuit!

Send us your photos of you in your blue Morphsuits and you could be our October Morph of the Month. There are a further two Morphsuits up for grabs, so make sure your photo stands out! Email your photo to info@jdrf.org.uk, or send it to us through Facebook or Twitter.

Despite this, only 6% of those included in the survey received all nine of the NICE recommended key care processes during the year (care processes include cholesterol and blood pressure measurements and eye screening). Although this figure is on the increase, it is well behind the over 50% of adults with diabetes who receive all the care processes. 

You may have seen reports in the newspapers this week that eye clinics cannot cope with demand for sight saving drugs.

The article refers to people with a condition called wet age-related macular degeneration (AMD) and states that they cannot get the drugs they need in time. As eye disease is a known complication of type 1 diabetes, does this have any implications for people with type 1?

Thankfully, no. Wet AMD is caused when blood vessels in the eye leak and affect vision. In this way it is similar to diabetic eye disease, but wet AMD progresses much, much faster.

For wet AMD there is a really short window of a few weeks where people need to be treated if their doctors are to prevent vision loss. The drugs used to treat wet AMD are similar to those used to treat diabetic eye disease, so you may see Avastin or Lucentis mentioned in articles about this subject. But in wet AMD, these drugs are only effective in the very short time before scar tissue has built up. The problem highlighted in press reports this week is that eye clinics have a backlog of people waiting to be seen so some people are not getting the drugs in time.

Because diabetic eye disease develops much more slowly than wet AMD, there are signs that it is developing years before any vision problems occur. Because the window in which treatment can begin is much larger for people with type 1, the backlog issues that some clinics are experiencing should not significantly affect the care of people with type 1.

Diabetic eye disease can develop in people who have had type 1 for a long time. The risk of developing eye disease is linked to the difficulty in controlling blood glucose levels, because prolonged periods of high blood glucose leads to damage to the small blood vessels in the eye. The risk of developing long term complications of living with type 1 is falling as our understanding of how to control glucose levels in the body grows, but as people with type 1 can still develop these complications JDRF is committed to developing new treatments specifically for these long term complications of type 1, through our ‘treat’ research pathway.